

1 **Type I IFN signaling mediates NET release to promote *Mycobacterium***
2 ***tuberculosis* replication and granuloma caseation**

3 Chanchal Sur Chowdhury¹, Rachel L. Kinsella¹, E. Michael Nehls¹, Sumanta K. Naik¹,
4 Daniel S. Lane², Priyanka Talukdar², Sthefany M. Chavez¹, Asya Smirnov¹, Wendy
5 Beatty¹, Darren Kreamalmeyer¹, Joshua T. Mattila², Christina L. Stallings^{1*}

6
7 ¹Department of Molecular Microbiology, Center for Women's Infectious Disease
8 Research, Washington University School of Medicine, St. Louis, MO 63110, USA

9
10 ²Department of Infectious Diseases and Microbiology, University of Pittsburgh School of
11 Public Health, Pittsburgh, PA, 15261, USA

12
13 *Correspondence: stallings@wustl.edu

14
15 **Keywords:** neutrophils, tuberculosis, granuloma, type I interferon, NETosis, bacterial
16 pathogenesis

17
18 **SUMMARY**

19
20 Neutrophils are the most abundant cell type in airways of tuberculosis patients. Recent
21 investigations reported induction of neutrophil extracellular traps (NETs) during
22 *Mycobacterium tuberculosis* (*Mtb*) infection, however, the molecular regulation and
23 impact of NETosis on *Mtb* pathogenesis is unknown. We find that in response to *Mtb*

24 infection in neutrophils, PAD4 citrullinates histones to decondense chromatin that gets
25 packaged into vesicles for release as NETs in a manner that can maintain neutrophil
26 viability and promote *Mtb* replication. Type I interferon, which has been associated with
27 NETosis in numerous contexts but without a known mechanism, promotes formation of
28 chromatin-containing vesicles and NET release. Analysis of nonhuman primate
29 granulomas supports a model where neutrophils are exposed to type I interferon from
30 macrophages as they migrate into the granuloma, where they release NETs that
31 contribute to necrosis and caseation. Our data reveals NETosis as a promising target to
32 inhibit *Mtb* replication and granuloma caseation.

33

34 **INTRODUCTION**

35

36 Tuberculosis (TB) remains a leading cause of death due to infectious disease. The 1.5
37 million TB-associated deaths in 2020 was the first increase in over a decade¹. Possible
38 outcomes of pulmonary *Mycobacterium tuberculosis* (*Mtb*) infection include pathogen
39 clearance, latent tuberculosis infection (LTBI), and active tuberculosis (ATB) disease,
40 the latter of which results in the clinical manifestations associated with TB. Both the
41 disease outcome and the pathology of TB are driven by the type of immune response
42 mounted by the host. Thus, it is imperative to better understand what immune
43 responses protect against versus promote *Mtb* infection to inform vaccine and host-
44 directed therapy development.

45

46 Neutrophils are the most abundant and predominantly-infected cell type in the sputum²,
47 bronchoalveolar lavage (BAL) fluid³, and caseum contents from resected lung tissue of
48 active TB patients². Studies of TB in mice^{4–17}, nonhuman primates^{18–21}, and humans^{9,22–}
49 ²⁸ have identified a correlation between neutrophil abundance and increased disease
50 severity. In contrast to their antibacterial role in numerous other infectious diseases²⁹,
51 neutrophils in TB have impaired capacity for killing phagocytosed *Mtb*^{30–32}. However,
52 there are studies supporting a protective role for neutrophils during *Mtb* infection, where
53 neutrophils were required to restrict *Mtb* growth in human whole blood *ex vivo*^{33,34}.
54 Isolated human neutrophils have also been shown to restrict *Mtb* replication³⁵,
55 particularly in the presence of TNF α ³⁶. These data suggest that there could be a
56 protective role for neutrophils during *Mtb* infection and highlight that the mechanisms
57 underlying how neutrophils impact *Mtb* replication and disease progression remain open
58 questions in the field.

59
60 In response to *Mtb* infection, neutrophils deploy a number of defenses including the
61 release of granules containing antimicrobial molecules and the extrusion of neutrophil
62 extracellular traps (NETs)^{9,33,37–39}. Markers for neutrophil NETosis are present in
63 necrotic lesions in resected lungs and in the plasma from active TB patients^{9,40–42},
64 suggesting an association between NETosis and active TB disease. NETosis is the
65 process by which neutrophils undergo histone citrullination^{43,44}, chromatin
66 decondensation⁴⁵, and release of web-like chromatin structures decorated with
67 antimicrobial granule proteins with the potential to bind, trap, and kill pathogens^{46–48}.

68 *Mtb*-induced NETs are unable to kill the bacteria³⁸, but can be bound and phagocytosed
69 by macrophages to impact macrophage inflammatory responses during infection³⁹.

70

71 Although very little is known about the molecular processes governing NETosis during
72 *Mtb* infection, a recent study showed that antibody-mediated blocking of GM-CSF
73 signaling in *Mtb*-infected mice increased neutrophil accumulation and NETosis, as
74 indicated by staining for citrullinated histone 3 (H3Cit)⁹. Global deletion of type I
75 interferon (IFN) receptor (IFNAR) decreased neutrophil accumulation and NETosis in
76 GM-CSF signaling deficient mice. In addition, *Mtb* infection of C3HeB/Fej mice, which
77 are more susceptible to infection than C57BL/6J mice and exhibit higher levels of type I
78 IFN signaling during infection, also resulted in signs of NETosis in the lungs⁹. However,
79 deletion of IFNAR specifically in neutrophils decreased neutrophil accumulation but not
80 the levels of citrullinated histones in neutrophils, suggesting that type I IFN functions
81 through other cell types to impact NETosis and leaving open the question of how type I
82 IFN directly controls neutrophil responses. Thus, the cell biology and molecular
83 regulation of NETosis within neutrophils during *Mtb* infection is still mostly undefined.

84

85 In this study, we dissect the cellular process of NETosis in response to *Mtb* and its
86 direct effect on bacterial replication and pathogenesis *in vitro* and *in vivo*. We discover
87 that during *Mtb* infection, neutrophils undergo a form of NET release where
88 decondensed chromatin is packaged in vesicles and released from the cell in a manner
89 that can maintain host cell viability. *Mtb*-induced NET release specifically requires
90 peptidyl arginine deiminase 4 (PAD4)-mediated histone citrullination. Unlike PAD4, type

91 I IFN signaling within neutrophils does not affect histone citrullination but instead
92 promotes the formation of the chromatin containing vesicles that will be released as
93 NETs. Analysis of markers for NETosis in *Mtb*-infected nonhuman primates (NHPs)
94 support a model where neutrophils are recruited to necrotic regions that contain *Mtb*
95 bacilli where they are exposed to type I IFN from epithelioid macrophages and undergo
96 NETosis, contributing to necrosis and the formation of caseum. Furthermore, we
97 demonstrate that NETs can directly promote *Mtb* replication and pathogenesis, thus
98 identifying a promising pharmacological target to control both pathogen replication and
99 the pathology associated with severe TB disease.

100

101 **RESULTS**

102

103 ***Mtb* induces NET release by mouse neutrophils**

104 To dissect the process and impact of NETosis during *Mtb* infection, we infected
105 neutrophils isolated from wild-type (WT) C57BL/6J mice with a strain of *Mtb* Erdman
106 expressing GFP^{12,13} at a multiplicity of infection (MOI) of 20 and visualized NETosis
107 using fluorescent confocal microscopy (Figure 1A). Neutrophils were identified by
108 staining with an anti-Ly6G antibody and an antibody specific for citrullinated histone 3
109 (H3Cit) was used to monitor the initial step of NETosis. On average, 5.1% of neutrophils
110 in cultures infected with *Mtb* were H3Cit positive by 4 hours post infection (hpi) as
111 compared to 0.4% in mock infected cultures (Figures 1B and 1C). By 18 hpi with *Mtb*,
112 56.7% of neutrophils were H3Cit positive in contrast to 0.6% in mock infected cultures
113 (Figures 1B and 1C). We quantified released NETs by counting extracellular H3Cit

114 positive web-like structures using the Ridge Detection plugin⁴⁹ of Fiji⁵⁰ (Figure S1). We
115 did not detect any released H3Cit positive webs in mock-infected cells at 4 hours, but
116 1.3 webs per 100 cells were detected at 4 hpi with *Mtb*. By 18 hpi with *Mtb*, we detected
117 an average of 22.7 webs per 100 cells (Figure 1C). To better visualize released NET
118 structures, we performed scanning electron microscopy (SEM) with mock or *Mtb*-
119 infected neutrophils. We were able to detect released NET structures at both 4 and 18
120 hpi with *Mtb*, but not in mock infected cells at either time point (Figure 1D, red arrows).
121 In addition, SEM revealed extracellular *Mtb* bacilli directly associated with the NETs
122 (Figure 1D, yellow arrows). Together these data demonstrate that some murine
123 neutrophils will release NETs in response to *Mtb* infection by 4 hpi, and this number of
124 NETotic neutrophils increases in response to *Mtb* by 18 hpi. These results also provide
125 the first evidence of *Mtb* induced NETosis by mouse bone marrow neutrophils *in vitro*.

126

127 **NETs released in response to *Mtb* infection differ structurally from PMA and** 128 **ionomycin induced NETs**

129 To determine whether NETosis in response to *Mtb* infection resembled NETosis in
130 response to other stimuli, we compared neutrophils infected with *Mtb* to neutrophils
131 treated with two well-studied chemical stimuli of NETosis, phorbol myristate acetate
132 (PMA) and ionomycin. PMA activates phosphokinase C (PKC) and ERK signaling,
133 which induces NADPH oxidase-dependent NETosis^{46,51}. In contrast, ionomycin
134 increases cytosolic calcium levels, which induces NETosis independent of NADPH
135 oxidase^{52,53}. Compared to PMA and ionomycin, *Mtb* induced significantly less histone
136 citrullination after 4 hours of incubation (Figure S2A and S2B), however, after 18 hours

137 of infection or treatment, all three conditions induced >50% H3Cit positivity, with *Mtb*
138 infection resulting in a significantly higher percentage of H3Cit positive cells compared
139 to PMA (Figures 2A and 2B). Despite the higher percentage of H3Cit positive cells, *Mtb*
140 infection and PMA treatment resulted in a similar number of released NETs. The most
141 striking observation was the difference in the thickness of the NETs released, where
142 *Mtb* infection led to the release of significantly thinner strands of H3Cit coated DNA than
143 PMA or ionomycin treatment (Figures 2A and 2B). SEM imaging of *Mtb*-infected and
144 PMA-treated neutrophils provided a higher resolution of the NET ultrastructure and
145 revealed that neutrophils released thin threads of DNA in response to *Mtb* infection
146 whereas PMA treatment resulted in the release of larger chromatin bundles (Figure 2C).
147 In addition, contrary to PMA treatment that induced cell flattening of neutrophils, *Mtb*
148 infected neutrophils retained their round morphology during the process of NETosis
149 (Figures 2C and S2C), suggesting different mechanisms of NETosis in responses to
150 these two stimuli.

151

152 ***Mtb* infected neutrophils package chromatin in vesicles for release and can**
153 **maintain viability during NET release**

154 NETosis has historically been defined as a suicidal cell death process⁴⁷. However, the
155 thinner NETs released from *Mtb* infected neutrophils and the observation that the *Mtb*-
156 infected NETotic neutrophils maintain their round morphology (Figures 1D and 2C) is
157 reminiscent of the recently described process of vital NET release where the NETotic
158 neutrophil retains its viability along with effector functions^{54,55}. To investigate if
159 neutrophils maintain viability during NET release in response to *Mtb* infection, we

160 included the Zombie Viability Dye (BioLegend) to stain cells with compromised plasma
161 membrane integrity in our microscopy experiments. At 18 hpi with *Mtb* there was a
162 significantly lower frequency of (21%) Zombie Dye positive cells than observed in
163 cultures following 18 hours of PMA or ionomycin treatment (69% and 84% Zombie⁺,
164 respectively), despite having similarly high levels of H3Cit positivity and released NETs
165 (Figures 3A and 3B). When we specifically quantified the viability of H3Cit⁺ neutrophils,
166 only an average 18% of H3Cit⁺ cells were Zombie⁺ at 18 hpi with *Mtb*, as compared to
167 an average of over 90% H3Cit⁺ cells being Zombie⁺ after PMA or ionomycin treatment
168 (Figure 3B). These data indicate that some neutrophils maintain viability following NET
169 release in response to *Mtb* infection.

170

171 Vital NET release occurs via nuclear envelope blebbing of decondensed chromatin into
172 vesicles that are subsequently exocytosed from the cell^{54,56,57}. To determine if *Mtb*-
173 induced NETosis exhibits similar subcellular morphological features to vital NET
174 release, we performed ultrastructure analysis of neutrophils after 4 and 18 hours of
175 infection with *Mtb*, mock infection, or treatment with PMA using transmission electron
176 microscopy (TEM) (Figure 3C). *Mtb* infection and PMA treatment induced increased
177 vesicle formation by 4 hours as compared to mock infected controls (Figures 3C and
178 3D). By 4 hours we were also able to identify vesicles containing decondensed
179 chromatin consisting of DNA strands exhibiting a “beads on a string” appearance in both
180 *Mtb*-infected and PMA-treated cultures, but not in mock infected cultures (Figures 3C
181 (blue arrows), 3E, and S3A). The number of vesicles containing decondensed
182 chromatin per cell was similar in cultures following *Mtb* infection or PMA treatment at

183 both 4 hours and 18 hours (Figure 3E), indicating that this was not a feature unique to
184 maintained viability during NET release. Some chromatin containing vesicles also
185 contained *Mtb* (Figure 3C), suggesting that vesicles containing chromatin were fusing
186 with *Mtb*-containing vesicles. During both *Mtb* infection and PMA treatment, release of
187 vesicles through the plasma membrane could be observed (Figures S3B,C). The only
188 morphological feature noted to be different during PMA treatment versus *Mtb* infection
189 was that by 4 hours the PMA-treated cells contained vesicles harboring electron dense
190 material that were not observed in *Mtb* infected cells at this time point (Figures 3C and
191 3F). By 18 hpi with *Mtb*, some cells had formed the vesicles containing electron dense
192 material, but still to a lesser extent than during PMA treatment at this time point (Figure
193 3F). Therefore, the abundance of the electron dense material is correlated with
194 increased cell death during NETosis. We were able to identify some PMA-treated cells
195 with vesicles that contained the electron dense material uncoiling into decondensed
196 "beads on a string" chromatin (Figure S3D), suggesting that this electron dense material
197 could represent condensed chromatin. Together, these results support a model where
198 during *Mtb* infection, neutrophils release NETs via vesicles in a manner that can
199 preserve plasma membrane integrity.

200

201 **Histone citrullination during *Mtb*-induced NET release is PAD4-dependent**

202 Histone citrullination by PAD enzymes is critical for the initial chromatin decondensation
203 that allows for NETosis following most stimuli⁵⁸⁻⁶⁰, including during *Mtb* infection where
204 pretreatment with the pan-PAD inhibitor Cl-amidine inhibited *Mtb* induced NETosis by
205 human neutrophils⁶¹. PAD4 is the primary PAD enzyme expressed in neutrophils and

206 has been shown to be essential for NETosis in response to a number of different stimuli
207 including lipopolysaccharide, lipoteichoic acid, fungal zymosan, and TNF α ^{44,52,59,60,62,63}.
208 However, NET formation in response to other stimuli, such as *Klebsiella pneumoniae*,
209 *Aspergillus fumigatus*, rodent-specific pneumovirus, and influenza virus
210 A/WSN/33/H1N1, occurs independent of PAD4⁶⁴⁻⁶⁸. To determine if *Padi4*, the gene
211 that encodes PAD4, is required for NETosis during *Mtb* infection, we infected WT and
212 *Padi4*^{-/-} neutrophils with *Mtb* for 18 hours and monitored NETosis by fluorescent
213 microscopy. Genetic inhibition of *Padi4* led to an almost complete loss of H3Cit positivity
214 and released NETs during *Mtb* infection (Figures 4A and 4B). We also quantified H3Cit
215 positivity by flow cytometry and observed a significantly lower frequency of H3Cit⁺
216 *Padi4*^{-/-} neutrophils compared to WT neutrophils at 18 hpi (Figure 4C). Moreover, PAD4-
217 deficient neutrophils harbored a significantly reduced number of DNA-filled vesicles per
218 cell upon stimulation with *Mtb* at 18 hpi (Figures 4D-E), demonstrating that PAD4 is
219 required for histone citrullination and NETosis during *Mtb* infection.

220

221 **Type I IFN regulates NET release, but not histone citrullination, during *Mtb*** 222 **infection**

223 Type I IFN signaling was shown to impact levels of NETosis in susceptible mice, but this
224 role was proposed to not be neutrophil intrinsic based on retained H3Cit staining in mice
225 deleted for *Ifnar1* specifically in neutrophils⁹. Type I IFN signaling is associated with
226 increased NETosis in multiple other contexts as well^{69,70}, although the exact role for
227 type I IFN signaling is still unknown in all cases. We directly investigated whether type I
228 IFN signaling within neutrophils impacts NETosis during *Mtb* infection by infecting WT

229 and *Ifnar1*^{-/-} neutrophils with *Mtb* for 18 hours and monitoring histone citrullination and
230 NET release by microscopy and flow cytometry. Similar to what was observed *in vivo*⁹,
231 loss of type I IFN signaling in neutrophils had no effect on the levels of H3Cit in
232 neutrophils during *Mtb* infection (Figures 4A-C). However, we observed a significant
233 decrease in the released NETs from *Ifnar1*^{-/-} neutrophils compared to WT neutrophils
234 during *Mtb* infection (Figures 4A and 4B). These data suggested that type I IFN
235 signaling in neutrophils regulates a step of NETosis after histone citrullination.
236 Therefore, we investigated whether loss of type I IFN signaling was affecting the
237 formation of vesicles containing decondensed chromatin. *Mtb* infection of *Ifnar1*^{-/-}
238 neutrophils resulted in significantly fewer chromatin filled vesicles per cell by 4 hpi as
239 compared to WT neutrophils (Figures 4D-F). At 18 hpi, the numbers of total vesicles
240 and vesicles containing decondensed chromatin per cell was still lower in *Ifnar1*^{-/-}
241 neutrophils compared to WT neutrophils, indicating that the defect in vesicle number
242 was not merely a delay in the NETosis process, but was a block prior to vesicle
243 formation. Together these studies demonstrate that histone citrullination during *Mtb*
244 infection is PAD4-dependent, whereas the release of citrullinated DNA is regulated by
245 type I IFN signaling in neutrophils. This newly discovered neutrophil-intrinsic role for
246 type I IFN in NET release could also explain why previous studies observed that
247 deletion of *Ifnar1* in neutrophils resulted in decreased tissue pathology without affecting
248 H3Cit levels⁹.

249

250 **NETs directly promote replication of *Mtb* *in vitro* and *in vivo***

251 Depletion of neutrophils in some susceptible mice can reverse high bacterial
252 burdens^{8,9,11,12}, however, it remains unknown how mechanistically neutrophils elicit
253 effects on *Mtb* replication. We examined whether NETs could directly contribute to *Mtb*
254 survival and replication by infecting WT and *Padi4*^{-/-} neutrophils with *Mtb* and monitoring
255 bacterial burden at 48 hpi by plating for colony forming units (CFU). *Mtb* burdens were
256 higher in cultures containing neutrophils than when *Mtb* was grown alone in the same
257 media (Figure 5A), indicating that neutrophils can directly promote *Mtb* replication. In
258 contrast, the higher bacterial burdens were completely reversed in cultures of *Mtb*-
259 infected *Padi4*^{-/-} neutrophils, where *Mtb* grew to similar levels as in cultures lacking
260 neutrophils (Figure 5A). These data indicate that NETosis is a contributor to *Mtb*
261 replication in the presence of neutrophils. In addition, deletion of *Ifnar1* also resulted in
262 lower levels of *Mtb* replication compared to WT neutrophils (Figure 5A), supporting a
263 role for NETosis in promoting *Mtb* replication.

264

265 Publicly available transcriptomic data from the lungs of *Mtb*-infected mice⁷¹ indicates
266 that *Mtb* infection does not upregulate *Padi4* expression in WT C57BL/6J *in vivo* (Figure
267 5B). In contrast, C3HeB/FeJ mice infected with the Lineage 2 *Mtb* strain HN878
268 significantly induced *Padi4* transcript production in their lungs compared to uninfected
269 mice or infected C57BL/6J mice (Figure 5B)⁷¹. H3Cit signal has also been detected in
270 the lungs of *Mtb*-infected C3HeB/FeJ mice in prior studies⁹. Therefore, to investigate
271 how NETosis impacts *Mtb* replication *in vivo*, we infected C3HeB/FeJ mice with *Mtb*
272 HN878 and chemically inhibited NETosis with daily intraperitoneal (IP) injections with
273 the pan-PAD inhibitor BB-CI-amidine (Cayman Chemical Company) (Figures S4A and

274 S4B) starting at 11 dpi until harvesting lungs for analysis of inflammation, histone
275 citrullination, and bacterial burdens at 21 dpi (Figure 5C). Histological analysis of lung
276 lesions in BB-Cl-amidine or DMSO vehicle-treated *Mtb*-infected mice demonstrated that
277 neutrophils accumulated in the lungs of all infected mice, but there was significantly
278 more H3Cit staining in the DMSO vehicle-treated *Mtb*-infected mice (Figures 5D and
279 S5), indicating that BB-Cl-amidine was effective at blocking histone citrullination in
280 neutrophils during *Mtb* infection of C3HeB/FeJ mice. Flow cytometry analysis of lungs at
281 21 dpi revealed that BB-Cl-amidine-treated *Mtb*-infected C3HeB/FeJ mice accumulated
282 more neutrophils and B cells in the lungs, but did not exhibit any other significant
283 differences in cell populations as compared to DMSO vehicle-treated *Mtb*-infected mice
284 (Figure S4C). Blocking NETosis in *Mtb*-infected C3HeB/FeJ mice with BB-Cl-amidine
285 resulted in significantly lower bacterial burdens in the lungs and spleens at 21 dpi
286 (Figure 5E), despite still accumulating high levels of neutrophils (Figure S4C),
287 suggesting that NETosis directly contributes to *Mtb* replication *in vivo* and can be
288 chemically inhibited to control *Mtb* pathogenesis.

289

290 **NETosis is associated with necrotic microenvironments in primate granulomas**

291 In addition to the effects of NETosis on *Mtb* replication, we were interested in how
292 NETosis contributes to granuloma-level pathology in humans. While most mouse strains
293 do not develop the diverse range of lesion types observed in humans, *Mtb*-infected
294 cynomolgus macaques experience the full spectrum of pathology seen in human TB
295 and develop granulomas that are equivalent to their human counterparts^{19,72}. Macaque
296 granulomas contain all the microenvironments that human granulomas do, including

297 non-diseased lung adjacent to the granuloma, the T- and B cell-rich lymphocyte cuff, the
298 epithelioid macrophage region, and, in many granulomas, a necrotic core⁷³. Neutrophils
299 experience different stimuli in each region^{21,72} and we took advantage of this feature in
300 granulomas from cynomolgus macaque with active TB to identify relationships between
301 NETosis and different granuloma microenvironments.

302

303 We found substantial variation in the abundance of H3Cit⁺ and H3Cit⁻ neutrophils per
304 granuloma (Figure 6A-C) in lesions from cynomolgus macaques. H3Cit⁺ neutrophils
305 were abundant at the interface of epithelioid macrophages and caseum in necrotic
306 granulomas (Figure 6B) whereas non-necrotic granulomas contained far fewer H3Cit⁺
307 cells (Figure 6C). When we quantified the number of H3Cit⁺ cells/granuloma, we found
308 that non-necrotic granulomas contained significantly fewer H3Cit⁺ cells than necrotic
309 granulomas (median \pm SEM: non-necrotic granulomas 0.0136 \pm 0.0036 versus necrotic
310 granulomas 0.0863 \pm 0.0160; Figure S6). Granulomas in close spatial proximity often had
311 substantially different phenotypes regarding the abundance of NETotic neutrophils
312 (Figure 6A) and we noted these differences could occur within the same granuloma if
313 that granuloma contained multiple neutrophilic or necrotic foci (Figure 6D).

314

315 We also noted an inverse relationship between S100A9 (our neutrophil marker) and
316 H3Cit expression. This was seen in regions where strong S100A9 staining coincided
317 with intact-appearing nuclei and less H3Cit staining (Figure 6D, region 1) whereas
318 neutrophils in regions with less S100A9 staining had DNA that was more diffuse and
319 stronger H3Cit expression (Figure 6D, region 2). This inverse relationship is also visible

320 when independent necrotic granulomas were compared (Figure 6A; blue arrowhead:
321 H3Cit^{low}S100A9^{high}, pink arrowhead: H3Cit^{high}S100A9^{low}). When we examined individual
322 neutrophils undergoing NETosis in tissue adjacent to granuloma's central regions
323 (Figure 6D, region 3), we observed that H3Cit⁺ DNA appeared as if it was being
324 discharged from these cells and this was accompanied by a flow of S100A9 protein in
325 the same direction as the H3Cit⁺ DNA, suggesting that cytoplasmic contents were being
326 released into the extracellular milieu as part of this process *in vivo*. Taken together, our
327 observations demonstrate that NETosis is a terminal event for neutrophils recruited to
328 necrotic primate granulomas but also highlight that this outcome varies by granuloma
329 and is related to the granuloma's morphology. Moreover, NETotic neutrophils are
330 important contributors to the milieu of highly-degraded DNA in caseum, thus providing a
331 link between NETosis and caseation in necrotic granulomas.

332

333 **NETosis occurs in proximity to caseum and IFN α 2-expressing epithelioid** 334 **macrophages**

335 Our *in vitro* data demonstrated that type I IFN induces NET release during *Mtb* infection.
336 Therefore, we investigated how NETosis within granulomas relates to type 1 IFN
337 expression by staining macaque granulomas for IFN α 2, H3Cit, and CD11c, an antigen
338 that is broadly expressed by granuloma macrophages (Figure 7). As previously noted,
339 H3Cit⁺ cells were present in the space between caseum and CD11c⁺ epithelioid
340 macrophages (Figure 7A, left). When we visualized the IFN α 2 fluorescence, we found
341 that many epithelioid macrophages stained positively for IFN α 2 (Figure 7A, right). To
342 confirm the likelihood that these cells were producing IFN α 2, we also stained these

343 lesions for phosphorylated IRF3 (pIRF3), a transcription factor that regulates IFN α 2
344 expression⁷⁴. The pIRF3 staining mirrored our IFN α 2 staining in epithelioid
345 macrophages (Figure 7B, right), indicating that the epithelioid macrophages surrounding
346 the H3Cit⁺ cells are expressing IFN α 2. Furthermore, we confirmed that although
347 neutrophils may be present throughout a granuloma (Figure 7B), H3Cit⁺ neutrophils
348 were restricted to necrotic regions (Figure 7A) between the IFN α 2⁺ epithelioid
349 macrophages and caseum.

350 To better understand how NETosis and type 1 IFN expression are linked in lesions with
351 poor immune control, we examined samples of TB pneumonia, a severe form of disease
352 characterized by overwhelming inflammation and multiple caseous foci. Studying this
353 lesion type gave us the ability to investigate how NETosis varied with IFN α 2 expression
354 in highly inflamed non-necrotic and necrotic regions (Figure 7C). As with necrotic
355 granulomas, we found that NETotic neutrophils were only present at interface of pIRF3⁺
356 epithelioid macrophages and caseum (Figure 7C, region 1). We also observed small
357 aggregates of pIRF3⁺ macrophages in non-necrotic regions and these regions
358 contained H3Cit⁺ neutrophils (Figure 7C, region 2). When we examined the integrity of
359 the nuclei in the center of these regions by comparing the DAPI staining across the field
360 of view, we noted a loss of nuclear integrity in the center of these aggregates, indicating
361 that these foci represented sites of developing necrosis. These observations suggest
362 that neutrophils migrate to necrotic foci, even at the earliest stages of caseation, and
363 these cells are exposed to type 1 IFN before they undergo NETosis. This suggests that
364 the combination of macrophage type 1 IFN expression, neutrophil recruitment, and
365 neutrophil NETosis contribute to development of caseous necrosis in primate

366 granulomas. In addition, NETs can induce type I IFN expression^{75,76}, potentially
367 providing evidence for a positive feedback loop involving neutrophils, type I IFN
368 expression, and granuloma macrophages.

369 **DISCUSSION**

370 There is a growing appreciation for the association of increased neutrophil abundance
371 with active TB disease. However, it is still unknown if the presence of neutrophils in the
372 lungs of active TB patients is consequential, or if the neutrophils are bystanders reacting
373 to an uncontrolled infection. In particular, the details on how specific neutrophil
374 responses and effector functions impact TB disease have remained elusive. We have
375 used genetic and chemical approaches to show that a specific response by neutrophils,
376 NETosis, directly contributes to *Mtb* replication and pathogenesis. Contrary to the
377 antimicrobial nature associated with NETs, we find that *Mtb* survives exposure to NETs
378 and can exploit NETosis to promote replication *in vitro*. This is particularly surprising
379 given that neutrophil granule proteins that are released on NETs have been shown to
380 inhibit *Mtb* replication when added to cultures of *Mtb* or *Mtb*-infected macrophages *in*
381 *vitro*⁷⁷⁻⁸⁰. Therefore, the mechanisms by which *Mtb* defends itself against the
382 antimicrobial effects of NETs and how NETosis promotes *Mtb* replication remain
383 unknown. Many bacterial species secrete nucleases to utilize extracellular DNA as a
384 nutrient source or to degrade NETs as a defense mechanism^{81,82}. *Mtb* has been shown
385 to secrete a nuclease, Rv0888, that can degrade DNA and RNA⁸³, but its role in *Mtb*
386 pathogenesis has yet to be elucidated. The process of NETosis could also release other
387 nutrients from neutrophils that promote *Mtb* growth. In addition, NETs and the proteins
388 that accompany neutrophil degranulation are associated with lung damage^{9,84-86} and in

389 granulomas the collateral damage these factors cause to nearby cells, including
390 macrophages, could inhibit antimicrobial functions and facilitate release of nutrients
391 from bystander cells. Our studies highlighted a close association between NETosis and
392 caseum in granulomas, specifically in a region that has previously been identified as
393 harboring many bacteria⁷³. Therefore, the contribution of NETosis to granuloma
394 necrosis and caseation could be another mechanism by which NETosis promotes an
395 environment for *Mtb* to thrive. Moreover, by entangling but not killing the *Mtb*,
396 neutrophils undergoing NETosis could promote *Mtb* aggregation that protects the bacilli
397 from environmental and antibiotic stress. Indeed, extracellular *Mtb* aggregates have
398 been observed within the acellular rim of necrotic lesions⁸⁷⁻⁸⁹.

399
400 The process of caseation in granulomas is not well understood but our results showing
401 that NETotic neutrophils are prominent in the smallest caseous foci we could detect
402 suggests that neutrophilic infiltration and NETosis are consequential to the early
403 formation of caseum. We were not able to determine if NETosis is followed by necrosis
404 in adjacent macrophages, or if neutrophils are recruited to necrotic macrophages and
405 then undergo NETosis, or if both scenarios occur simultaneously, but all these options
406 may contribute to granuloma-level caseation. NETosis has been associated with
407 macrophage death by pyroptosis in murine models of sepsis⁹⁰, and further work
408 investigating interactions between neutrophils and epithelioid macrophages in macaque
409 granulomas may identify causal or temporal relationships between these behaviors and
410 caseation. Considering the link between neutrophilic inflammation and TB pathology,
411 the outcomes of neutrophil-driven caseation has implications for control of bacterial

412 dissemination, especially in settings where necrotic granulomas have the potential to
413 invade airways or blood vessels. NETosis may also contribute to the progression of
414 necrotic granulomas into cavitary lesions, a process that promotes active TB disease
415 and bacterial transmission. Taken together, these hypotheses support a paradigm that
416 links excessive neutrophilic inflammation and NETosis-driven caseation with reduced
417 control of TB at the lesion and systemic levels.

418

419 Our data highlights the association of NETosis with type I IFN production by epithelioid
420 macrophages but does not rule out type I IFN from other cell types. Alveolar
421 macrophages and plasmacytoid DCs (pDCs) also express type I IFN^{91,92}, and
422 neutrophils are likely to encounter these cells as they are recruited into granulomas. In
423 addition, our *in vitro* studies suggest that neutrophils themselves also produce sufficient
424 type I IFN to induce NET release. Despite the well-established connection between type
425 I IFN and NETosis, how type I IFN signaling contributes to NETosis remained elusive.
426 We have discovered that type I IFN signaling in neutrophils functions downstream of
427 histone citrullination to promote the formation of chromatin containing vesicles and their
428 release as NETs. Our findings reveal that there are multiple points that regulate
429 NETosis during *Mtb* infection while highlighting that histone citrullination can occur
430 without efficient release of NETs. The specific role for type I IFN signaling during these
431 later steps of NETosis could also be relevant to the other contexts where type I IFN
432 promotes NETosis and exacerbates disease, such as systemic lupus erythematosus
433 (SLE). In addition to this newly discovered neutrophil-intrinsic role for type I IFN
434 signaling during NETosis, type I IFN signaling in non-neutrophils promotes histone

435 citrullination in neutrophils in susceptible mice during *Mtb* infection⁹, highlighting another
436 way that type I IFN can regulate NETosis. In this regard, the histone citrullination
437 observed in neutrophils adjacent to IFN α 2-expressing epithelioid macrophages likely
438 results from IFN-regulated factors, and not necessarily type I IFN itself. In addition to a
439 role for type I IFN signaling in promoting NETosis, NETs themselves can induce type I
440 IFN production by pDCs and myeloid cells through toll like receptor 9 (TLR9) and
441 STING-dependent signaling pathways^{93–97}. Taken together, these features may
442 contribute to a cycle of NET-driven immunopathology where NETs promote epithelioid
443 macrophage type I IFN expression, and this activates a cascade of pathogenic
444 neutrophil- and type I IFN-regulated responses in granulomas. A number of studies
445 have linked increased and sustained levels of type I IFN signaling with TB pathology in
446 mice and humans^{14,24,98,99}. Based on our data that NETosis promotes *Mtb* replication
447 and pathogenesis, NETosis could contribute to the ways that type I IFN signaling
448 impedes control of *Mtb* infection. In addition to impacting type I IFN signaling, NETs can
449 modulate other myeloid cell activities, including cytokine production and
450 phagocytosis^{100,101}. NETosis also promotes the formation of low density neutrophils¹⁰²,
451 which are associated with poor TB outcomes^{103,104}. Therefore, the interactions between
452 NETotic neutrophils and other cell types within granulomas, and how these interaction
453 shape outcomes in TB, are complex and require further dissection.

454

455 The alarming rise of drug-resistant TB cases has made it clear that we are not equipped
456 to successfully battle the TB epidemic. There is growing interest in host-directed
457 therapies (HDT) that would be effective against both drug-sensitive and drug-resistant

458 *Mtb*. Herein, we identify NETosis as a potential HDT target and highlight points of
459 regulation of this process during *Mtb* infection. Our findings could also be applied to
460 other diseases where excessive neutrophilic inflammation and NETosis is linked to
461 pathology. This includes thrombosis where NETs provide the scaffold and stimulus for
462 thrombus formation¹⁰⁵. NETosis is also a prominent feature of lung pathology in
463 influenza^{106,107}, SIV infection¹⁰⁸, and COVID-19¹⁰⁹. Thus, better understanding of how
464 NETosis is regulated in different contexts could have broad implications for human
465 health.

466

467 **ACKNOWLEDGEMENTS**

468 This work was supported by NIH grants R01 AI132697 and U19 AI142784, a Burroughs
469 Wellcome Fund Investigators in the Pathogenesis of Infectious Disease Award, and the
470 Philip and Sima Needleman Center for Autophagy Therapeutics and Research to
471 C.L.S., Potts Memorial Foundation postdoctoral fellowship to R.L.K, Stephen I. Morse
472 Fellowship to S.K.N., and NIH grant T32 AI007172 to E.M.N. Work at the University of
473 Pittsburgh was supported by NIH grants R01 AI164970 and R21 AI167710, and funding
474 from the Wellcome Leap Delta Tissue Program to J.T.M.. We are grateful for the
475 assistance of Dr. Sanja Sviben, Dr. Praveen Krishnamoorthy, and Dr. James Fitzpatrick
476 at the Washington University Center for Cellular Imaging (WUCCI) with the scanning
477 electron microscopy and confocal microscopy studies, which is supported by
478 Washington University School of Medicine, the Children's Discovery Institute of
479 Washington University and St. Louis Children's Hospital (CDI-CORE-2015-505 and
480 CDI-CORE-2019-813) and the Foundation for Barnes-Jewish Hospital (3770).

481

482 **AUTHOR CONTRIBUTIONS**

483 The experiments were designed by C.S.C., J.T.M., and C.L.S.. The experiments were
484 executed by C.S.C., R.L.K., E.M.N, S.K.N., D.S.L., P.T., and J.T.M., with assistance
485 from A.S. and S.M.C.. W.B. assisted with TEM studies. C.S.C., J.T.M., and C.L.S.
486 analyzed the data. D.K. bred and maintained the mouse colonies. The manuscript was
487 written by C.S.C., J.T.M., and C.L.S. and all authors provided edits and comments on
488 drafts.

489

490 **DECLARATION OF INTERESTS**

491 The authors declare no competing interests.

492

493 **METHODS**

494 *Mtb* strains and bacterial cultures

495 *Mtb* Erdman expressing GFP (GFP-*Mtb*^{12,13}) was used in all *in vitro* experiments, wild-
496 type *Mtb* HN878 strain (kindly provided by Dr. Selvakumar Subbian) was used for the
497 mouse infections, and wild-type *Mtb* Erdman was used in the nonhuman primate
498 studies. *Mtb* strains were cultured at 37°C in 7H9 (broth) or 7H11 (agar) (Difco) medium
499 supplemented with 10% oleic acid/albumin/dextrose/catalase (OADC), 0.5% glycerol,
500 and 0.05% Tween 80 (broth). Cultures of GFP-*Mtb* were grown in the presence of
501 kanamycin (20 µg/ml) to ensure plasmid retention.

502

503 Mice

504 Adult mice (age 7–15 weeks) of both sexes were used and mouse experiments were
505 randomized. C57BL/6J (000664), *Padi4*^{-/-} (030315), and C3HeB/FeJ (000658) mice
506 were all purchased from Jackson Laboratory and bred in pathogen-free barrier facilities
507 at the Washington University in Saint Louis. *Ifnar1*^{-/-} mice were kindly provided by Drs.
508 Ashley Steed, Wayne Yokoyama, and Bob Schreiber. No blinding was performed during
509 animal experiments. All procedures involving animals were conducted following the
510 National Institute of Health guidelines for housing and care of laboratory animals and
511 performed in accordance with institutional regulations after protocol review and approval
512 by the Institutional Animal Care and Use Committee of The Washington University in St.
513 Louis School of Medicine. Washington University is registered as a research facility with
514 the United States Department of Agriculture and is fully accredited by the American
515 Association of Accreditation of Laboratory Animal Care. The Animal Welfare Assurance
516 is on file with OPRR-NIH. All animals used in these experiments were subjected to no or
517 minimal discomfort. All mice were euthanized by CO₂ asphyxiation, which is approved
518 by The Panel on Euthanasia of the American Veterinary Association.

519

520 Neutrophil isolation from mice

521 Bone marrow neutrophils were obtained using a single-step Percoll gradient¹¹⁰. Briefly,
522 murine bone marrow was flushed out of the tibia and the femur in HBSS supplemented
523 with 20 mM HEPES (Sigma) using a 23G needle (McKesson) and passed through a 70
524 µm cell strainer (CellTreat) after hypertonic lysis with of erythrocytes using a 0.2% NaCl
525 solution. Cells were pelleted and the entire bone marrow was resuspended in HBSS
526 without CaCl₂ and MgCl₂, 20 mM HEPES (Sigma), and 0.5% HI FBS (Gibco).

527 Neutrophils were purified by centrifugation for 30 min at 1,300xg on a discontinuous
528 Percoll gradient (GE Healthcare #17-0891-01) consisting of 62% (v/v) Percoll in HBSS,
529 20 mM HEPES (Sigma), and 0.5% HI FBS (Gibco). Neutrophils were recovered from
530 the bottom of the tube.

531

532 *In vitro* infection of neutrophils

533 Isolated bone marrow neutrophils were resuspended in HBSS and counted. 0.5×10^6
534 cells were transferred to a 24 well plate containing glass coverslips and RPMI 1640
535 supplemented with 10% Heat inactivated FBS and incubated for 45 minutes.
536 Logarithmically growing GFP-*Mtb* was counted after washing and sonicating in PBS to
537 separate clumps of bacteria. *Mtb* were opsonized for 1h with 5% normal mouse serum
538 (NMS) in RPMI before adding to the neutrophil cultures in the 24 well plate at an MOI of
539 20. Plates were centrifuged at 200xg for 10 minutes. For microscopy experiments, cells
540 plus bacteria were incubated for 30 minutes at 37°C and 5% CO₂ following
541 centrifugation before removing all non-phagocytoses bacteria and replacing the media
542 with RPMI 1640 supplemented with 10% Heat inactivated FBS, 1 mM CaCl₂ and 1mM
543 MgCl₂. For infections used to monitor bacterial burden, non-phagocytosed bacteria were
544 not removed.

545

546 Fluorescent microscopy and quantification

547 For fluorescent microscopy of neutrophils *in vitro*, neutrophils on coverslips were fixed
548 with 4% paraformaldehyde (PFA) and staining was performed with antibodies specific
549 for H3Cit (citrulline R2 + R8 + R17, Abcam Ab5103, 1:200), myeloperoxidase (MPO,

550 goat polyclonal R&D Systems, 1:200) or Ly6G (Clone 1A8, 1:200). DNA was labeled
551 with 5 µg/ml Hoechst 33342 (Molecular Probes). To detect cells with compromised
552 plasma membrane integrity indicative of cell death, neutrophils on cover slips were
553 treated with Zombie NIR (BioLegend, 1:1000) for 5 min before PFA fixation and staining
554 with Hoechst and other antibodies. A Nikon A1Rsi confocal microscope coupled with
555 NIS software was used to take Z-stack images with a 60x oil immersion objective. ND2
556 files of Z-Stack confocal images were merged using FIJI software. Fields that were
557 imaged and used for quantification were selected randomly based on areas containing
558 around 100 cells to keep the cell number consistent between groups or treatments.
559 Ridge detection analysis was performed on 8-bit images. Structures above the
560 threshold described in supplementary figure S1 were counted and measured.

561

562 Scanning electron microscopy (SEM)

563 Cultures on glass coverslips were washed with 0.15M cacodylate buffer warmed to
564 37°C and fixed overnight in a solution containing 2.5% glutaraldehyde and 2% PFA in
565 0.15 M cacodylate buffer at pH 7.4 that had been warmed to 37°C. Coverslips were
566 then rinsed in 0.15 M cacodylate buffer 3 times for 10 minutes each and subjected to a
567 secondary fixation in 1% osmium tetroxide in cacodylate buffer for one hour. Samples
568 were then rinsed in ultrapure water 3 times for 10 minutes each and dehydrated in a
569 graded ethanol series (30%, 50%, 70%, 90%, 100% x3) for 10 minutes each. Once
570 dehydrated, samples were loaded into a critical point drier (Leica EM CPD 300, Vienna,
571 Austria) that was set to perform 12 CO₂ exchanges at the slowest speed. Samples were
572 then mounted on aluminum stubs with carbon adhesive tabs and coated with 5 nm of

573 carbon and 6 nm of iridium (Leica ACE 600, Vienna, Austria). SEM images were
574 acquired on an FE-SEM (Zeiss Merlin, Oberkochen, Germany).

575

576 Transmission electron microscopy (TEM)

577 TEM of neutrophils has been described previously⁵⁴. Neutrophils either mock-infected or
578 infected with *Mtb* were released from the coverslips using 10mM EDTA for 5 min and
579 collected into a tube and pelleted. For ultrastructural analysis, samples were fixed in 2%
580 PFA/2.5% glutaraldehyde in 100 mM sodium cacodylate buffer for 2 h at room
581 temperature and then overnight at 4°C. Samples were washed in sodium cacodylate
582 buffer, embedded in 2.5% agarose, and postfixed in 2% osmium tetroxide (Ted Pella
583 Inc., Redding, CA) for 1 h at room temperature. After three washes in dH₂O, samples
584 were en bloc stained in 1% aqueous uranyl acetate (Electron Microscopy Sciences,
585 Hatfield, PA) for 1 h. Samples were then rinsed in dH₂O, dehydrated in a graded series
586 of ethanol, and embedded in Eponate 12 resin (Ted Pella Inc). Sections of 95 nm were
587 cut with a Leica Ultracut UCT ultramicrotome (Leica Microsystems Inc., Bannockburn,
588 IL), stained with uranyl acetate and lead citrate, and viewed on a JEOL 1200 EX
589 transmission electron microscope (JEOL USA Inc., Peabody, MA) equipped with an
590 AMT 8-megapixel digital camera and AMT Image Capture Engine V602 software
591 (Advanced Microscopy Techniques, Woburn, MA).

592

593 Plating for CFU from *Mtb*-infected neutrophil cultures

594 After 48 hours of incubation, neutrophils were lysed by addition of a final concentration
595 of 0.5% Triton X-100 (Sigma) directly into the medium. Lysates were 10-fold serially

596 diluted in 0.05% Tween 80 in PBS and plated on Middlebrook 7H11 agar plates. After 3-
597 4 weeks at 37°C in 5% CO₂, colonies were counted and total cell numbers were
598 calculated.

599

600 *Mtb* infection of mice

601 *Mtb* infection of mice have been previously described¹¹. Briefly, before infection,
602 exponentially replicating *Mtb* HN878 strain were washed in PBS + 0.05% Tween 80 and
603 sonicated to disperse clumps. 7- to 15-week-old female mice were exposed to 8×10^7
604 CFU of *Mtb* in an Inhalation Exposure System (Glas-Col), which delivers ~100 bacteria
605 to the lung per animal. At 24 hours post infection, the bacterial titers in the lungs of at
606 least two mice were determined to confirm the dose of *Mtb* inoculation. The dose
607 determined from these mice is assumed to represent the average dose received by all
608 mice in the same infection. Bacterial burden was determined by plating serial dilutions
609 of organ homogenates onto 7H11 agar plates. Plates were incubated at 37°C in 5%
610 CO₂ for 3 weeks prior to counting colonies.

611

612 Histology of mouse lung tissue

613 Lung tissue fixed in 4% PFA were dehydrated using sucrose gradient and mounted into
614 blocks using Fisher OCT in liquid nitrogen. Frozen lung sections were cut at 5 μm.
615 Antigen retrieval was performed for 5 min using 1% SDS. Samples were permeabilized
616 with 0.5% Triton X-100 in PBS containing 1% BSA for 5 min, blocked for 1 h using 5%
617 donkey serum and then incubated with a rabbit monoclonal H3Cit antibody (citruiline R2
618 + R8 + R17, clone EPR20358-120; Abcam) at 1:500 dilution overnight in a humidified

619 chamber at 4°C. Samples were washed with PBS and incubated with a Alexa Fluor 555
620 conjugated secondary antibody (Invitrogen, 1:200), Alexa Fluor 488 conjugated MPO
621 (Abcam, 1:200), Alexa Fluor 647 conjugated Ly6G antibody (BioLegend, 1:200), and
622 Hoechst (1:1000) for 1 h at room temperature. Samples were mounted after removing
623 tissue autofluorescence using Vector® TrueVIEW® Autofluorescence Quenching Kit. Z-
624 stack images of large 8x8 area under 10x objective were taken using a Nikon A1Rsi
625 confocal microscope coupled with NIS software, and mosaics were made with 20%
626 overlap to cover the entire lung section.

627

628 Flow Cytometry

629 Lungs were perfused with sterile PBS and digested at 37°C for 1 h with 625 µg/mL
630 collagenase D (Roche) and 75 U/mL DNase I (Sigma). Single cell suspensions stained
631 in PBS + 2% FBS in the presence of Fc receptor blocking antibody (BD Pharmingen)
632 and stained with the antibodies against the following mouse proteins: SiglecF (clone
633 E50-2440; BD Pharmingen), Ly6G (clone 1A8; BioLegend), CD11c (clone N418;
634 BioLegend), CD11b (clone M1/70; BioLegend), MHCII (clone M5/114.15.2; BioLegend),
635 CD45 (clone 30-F11; BioLegend), Ly6C (clone HK1.4; BioLegend), CD4 (clone RM4-5;
636 BioLegend), TCRβ (clone H57-567; BioLegend), CD8a (clone 53-6.7; BioLegend),
637 CD19 (clone 6D5; BioLegend). Cells were stained for 20 minutes at 4°C and then fixed
638 in 4% PFA (Electron Microscopy Sciences) for 20 minutes at room temperature. For
639 intracellular H3Cit staining, PFA fixed cells were permeabilized with BD perm/wash
640 buffer for 5 min. Cells were blocked with 2% BSA in PBS and then incubated with anti-
641 H3Cit antibody (citruiline R2 + R8 + R17, clone EPR20358-120; Abcam) overnight at

642 4°C. After incubation, cells were washed with PBS and incubated with Alexa Fluor 647
643 conjugated secondary antibody (Invitrogen,1:200) and anti-Ly6G antibody (clone 1A8;
644 BioLegend) for 1h at RT. Following incubation, cells were washed with PBS and
645 resuspended in FACS buffer. Flow cytometry was performed on a Cytex Aurora (Cytex
646 Biosciences). Spectral unmixing was performed using Cytex Aurora software and data
647 was analyzed with FlowJo (Tree Star Inc.). Gating strategies in Figure S7.

648

649 Immunofluorescence on nonhuman primate granulomas

650 Immunofluorescence was performed on granulomas from *Mtb*-infected cynomolgus
651 macaques (*Macaca fascicularis*) involved in completed studies at the University of
652 Pittsburgh that were approved by the University of Pittsburgh's IACUC. Animals used in
653 this study, by animal identifier and duration of *Mtb* infection (days post infection; dpi),
654 include 9409 (69 dpi), 907 (76 dpi), 18214 (84 dpi), 18314 (91 dpi), 1707 (94 dpi),
655 18514 (118 dpi), 18414 (125 dpi), 6409 (140 dpi), 4710 (254 dpi), 12603 (277 dpi), 9905
656 (464 dpi). All animals were infected with Erdman-strain *Mtb* via bronchoscopic
657 instillation except for monkey 4710, which was infected via aerosol route, and all were
658 monitored as previously indicated^{111,112} for the study's duration. At the end of the study,
659 the animals were all assessed to have active TB based on clinical and radiographic
660 features. Details for each animal are indicated in Table S1. Lung granulomas were
661 harvested from each animal at the time of necropsy and fixed in 10% neutral buffered
662 formalin and embedded in paraffin. 5- μ m thick sections were cut from these blocks and
663 used for staining. The samples included here were selected based on the presence of
664 granulomas and some sections contained multiple granulomas, thus bacterial burdens

665 per granuloma were not available for most of these lesions. Immunofluorescent staining
666 was performed as previously indicated^{19,21,72} for antigens including anti-
667 S100A9/calprotectin (clone MAC387; Thermo Fisher Scientific, Waltham, MA), anti-
668 histone H3 (citrullinated at R2+R8+R11, clone 11D3, Caymen Chemical, Ann Arbor,
669 MI), anti-CD11c (clone 5D11; Leica Biosystems, Deer Park, IL), and anti-IFN α 2 (rabbit
670 polyclonal; Thermo Fisher Scientific). Species- and isotype-specific secondary
671 antibodies were purchased from Jackson ImmunoResearch (West Grove, PA) or
672 Thermo Fisher Scientific. Where anti-S100A9 and anti-H3Cit were used in the same
673 section, H3Cit was stained with IgG1-specific secondary antibodies and S100A9 was
674 labeled with Thermo Fisher Scientific's Xenon labeling kit and used as a tertiary stain. A
675 second tissue section was stained in parallel and used as an isotype control with the
676 same secondary cocktail as a control to ensure the specificity of the staining. Coverslips
677 were mounted on slides using ProLong Gold Mounting Media with DAPI (Thermo
678 Fisher). 14-bit images of stained granulomas were acquired at 20x magnification on an
679 e1000 epifluorescence microscope (Nikon, Melville, NY) using a DS-Qi2 camera (Nikon)
680 and individual frames were stitched together at acquisition by Nikon Elements AR v4.50.
681 Image analysis was done on the ND2 image files with segmentation performed by
682 QuPath version 0.3.2¹¹³ and graphical representations of cell phenotypes were
683 prepared in CytoMAP version 1.4.21¹¹⁴.

684

685 **Statistical analysis for biological experiments**

686 All data are from at least two independent experiments. Samples represent biological
687 (not technical) replicates. No blinding was performed during animal experiments.

688 Statistical analyses were performed with Prism (v9.4.1; GraphPad Software) using
689 unpaired two-tailed Student's t tests, after the data were tested for normality, to
690 compare between two conditions or one-way ANOVA with Tukey's correction to perform
691 multiple comparisons. Sample sizes were sufficient to detect differences as small as
692 10% using the statistical methods described. When used, center values and error bars
693 represent means \pm SEM. $P < 0.05$ was considered significant. $P > 0.05$ was denoted
694 *, ** for $P < 0.01$, *** $P < 0.001$, and **** $P < 0.0001$. Only significant differences
695 are noted in the figures.

696

697 **FIGURE LEGENDS**

698 **Figure 1. *Mtb* induces NET formation by mouse neutrophils.**

699 **(A)** Schematic of experimental design for *in vitro* *Mtb* infection of murine bone marrow
700 neutrophils. Bone marrow neutrophils from C57BL/6J mice were cocultured with normal
701 mouse serum (NMS)-opsonized GFP-*Mtb* at an MOI of 20 or NMS (mock) for 4h and
702 18h before fixing with PFA and visualizing by confocal microscopy. BioRender.com
703 used in schematic.

704 **(B)** Representative confocal images of neutrophils stained for citrullinated histone 3
705 (H3Cit), the neutrophil marker Ly6G, and DNA (Hoechst). GFP-*Mtb* is also shown.
706 Magnification 60x.

707 **(C)** The percentage of Hoechst⁺ cells that were also H3Cit⁺ (top) and the number of
708 extracellular H3Cit⁺ webs per 100 Hoechst⁺ nuclei (bottom) per field under 60x objective
709 were quantified using ImageJ software and plotted. Each datapoint represents data
710 from one field and a total of 12 fields containing 20-200 cells/field were quantified and

711 compiled from 4 independent experiments. Bar graph of data represents
712 mean \pm SEM. **** $P < 0.0001$ determined by unpaired t test, comparing only within a
713 single timepoint.

714 **(D)** Representative scanning electron microscopy showing neutrophil morphology after
715 4 and 18 hpi with *Mtb* or following mock infection. Released NETs (red arrows) are
716 observed in association with extracellular *Mtb* (yellow arrows). Images on the right for
717 each time point are zoomed in from the region in the yellow box.

718

719 **Figure 2. NETs released in response to *Mtb* infection differ structurally from PMA**
720 **and ionomycin induced NETs.**

721 **(A)** Representative confocal images showing immunofluorescence staining of PFA fixed
722 bone marrow neutrophils from C57BL/6J mice infected with *Mtb* at an MOI 20 or treated
723 with PMA (100 nM) or ionomycin (5 μ M) for 18 h and stained for citrullinated histone 3
724 (H3Cit), the neutrophil marker myeloperoxidase (MPO), and DNA (Hoechst). GFP-*Mtb*
725 is also shown. Images on the right are zoomed in from the region in the white box.
726 White arrows denote NETs formed in each condition. Magnification 60x, zoomed in 2x.

727 **(B)** The percentage of Hoechst⁺ cells that were also H3Cit⁺ (left), the number of
728 extracellular H3Cit⁺ webs per 100 Hoechst⁺ nuclei (middle), and mean width of H3cit⁺
729 webs (right) per field at 18 h of *Mtb* infection or treatment with PMA or ionomycin (Iono)
730 under 60x objective were quantified using ImageJ software and plotted. Each datapoint
731 represents data from one field and a minimum of 6 fields containing 20-200 cells/area
732 were quantified and compiled from 2 independent experiments. Bar graph of data

733 represents mean \pm SEM. * $P < 0.05$; *** $P < 0.001$; **** $P < 0.0001$ by one-way
734 ANOVA with Tukey's correction.

735 **(C)** Representative scanning electron microscopy showing neutrophil morphology after
736 18 h of coculture with *Mtb* or treatment with PMA. Yellow arrows denote the flattening of
737 neutrophils in the presence of PMA. Clustered release of chromatin was observed
738 during PMA treatment compared to thread like NETs released during *Mtb* infection.
739 Images on the right are zoomed in from the region in the yellow box.

740

741 **Figure 3. *Mtb* infected neutrophils package chromatin in vesicles for release and**
742 **can maintain viability during NET release.**

743 **(A)** Representative confocal images showing bone marrow neutrophils from C57BL/6J
744 mice infected with GFP-*Mtb* at an MOI 20 or treated with PMA (100nM) or ionomycin
745 (Iono, 5 μ M) for 18h and stained for citrullinated histone 3 (H3Cit), cell death marker
746 (Zombie dye), and DNA (Hoechst). GFP-*Mtb* is also shown. White arrows indicate
747 Zombie negative neutrophils positive for H3Cit staining and associated with released
748 NETs. Magnification 60x, zoomed in 2x.

749 **(B)** Bar graphs showing quantification of immunofluorescence staining to detect H3Cit
750 positivity and neutrophil viability. The percentage of Hoechst⁺ cells that were H3Cit⁺
751 (top), the percentage of Hoechst⁺ cells that were Zombie⁺ (middle), and the percentage
752 of H3cit⁺ cells that were Zombie⁺ (bottom) per field under 60x objective were quantified
753 using ImageJ software and plotted. Each datapoint represents data from one field and a
754 minimum of 6 fields containing 30-200 cells/field for each condition were quantified and
755 compiled from 2 independent experiments. Bar graph of data represents

756 mean \pm SEM. * $P < 0.05$; *** $P < 0.001$; **** $P < 0.0001$ by one-way ANOVA with
757 Tukey's correction.

758 **(C)** Representative TEM images of neutrophils infected with *Mtb* at an MOI of 20, mock-
759 infected, or treated with PMA for 4h or 18h. Three representative cells per condition are
760 shown. Red boxes designate the region that was zoomed into for each cell and shown
761 in the right panels. Yellow arrows denote *Mtb*, blue arrows denote vesicles containing
762 “beads on a string” DNA and histone structures (decondensed chromatin vesicles), and
763 red arrows denote vesicles containing electron dense material.

764 **(D-F)** Quantification of different types of vesicles observed in neutrophils using TEM
765 after PMA treatment, *Mtb* infection, or mock infection. (D) Total vesicles per cell, (E)
766 vesicles containing decondensed chromatin, and (F) vesicles containing electron dense
767 material per cell at 4h and 18h following treatment or infection. Each datapoint
768 represents a single neutrophil and 6-20 neutrophils were used for quantification per
769 sample group from two independent experiments. Bar graph of data represents
770 mean \pm SEM. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$ determined
771 by one-way ANOVA with Tukey's correction, comparing only within a given timepoint.

772

773 **Figure 4. Molecular determinants of NETosis during *Mtb* infection.**

774 **(A)** Representative confocal images showing immunofluorescence staining of
775 neutrophils from WT, *Padi4*^{-/-}, and *Ifnar1*^{-/-} mice infected with GFP-*Mtb* at an MOI of 20
776 for 18h and stained for citrullinated histone 3 (H3Cit), a neutrophil marker (Ly6G), and
777 DNA (Hoechst). GFP-*Mtb* is also shown. Magnification 60x.

778 **(B)** The percentage of Hoechst⁺ cells that were also H3Cit⁺ (top) and the number of
779 extracellular H3Cit⁺ webs per 100 Hoechst⁺ nuclei (bottom) per field under 60x objective
780 were quantified using ImageJ software and plotted. Each datapoint represents a single
781 field and a minimum of 12 fields containing 20-200 cells/field were quantified and
782 compiled from 2 independent experiments. Bar graph of data represents the
783 mean \pm SEM. ** $P < 0.01$ and **** $P < 0.0001$ by one-way ANOVA with Tukey's
784 correction.

785 **(C)** Bar graph represents the percent of Ly6G⁺ cells that were also H3Cit⁺ as
786 determined by flow cytometry after 18 hpi with *Mtb* or mock infected. Neutrophils were
787 collected from WT, *Padi4*^{-/-}, and *Ifnar1*^{-/-} mice where each datapoint for a given strain
788 and condition represents a different mouse. N=4 mice for each genotype. Bar graph of
789 data represents mean \pm SEM. * $P < 0.05$ by one-way ANOVA with Tukey's
790 correction, compared within a single condition.

791 **(D-E)** Bar graphs showing quantification of different types of vesicles observed in
792 neutrophils using TEM after *Mtb* infection. (D) Total vesicles per cell and (E) vesicles
793 containing decondensed chromatin at 4h and 18h following infection. Each datapoint
794 represents a single neutrophil, where 5-10 neutrophils were used for quantification per
795 genotype. Bar graph of data represents mean \pm SEM. * $P < 0.05$; *** $P < 0.001$;
796 **** $P < 0.0001$ determined by one-way ANOVA with Tukey's correction, comparing
797 only within a given timepoint.

798 **(F)** Representative TEM images of bone marrow neutrophils from WT, *Padi4*^{-/-} and
799 *Ifnar1*^{-/-} mice infected with *Mtb* for 4h. Three representative cells per strain are shown.
800 Red boxes designate the region that was zoomed into for each cell and shown in the

801 right panels. *Mtb* (yellow arrow) and vesicles containing decondensed chromatin (blue
802 arrow) are labeled.

803

804 **Figure 5. NETs directly promote replication of *Mtb* *in vitro* and *in vivo*.**

805 **(A)** Bone marrow neutrophils from WT, *Padi4*^{-/-}, and *Ifnar1*^{-/-} mice were infected with
806 GFP-*Mtb* at an MOI of 20 or an equivalent amount of *Mtb* was cultured in the same
807 media without neutrophils for 48 hours. CFU/ml were determined by lysing the
808 neutrophils and plating dilutions of the entire well on 7H11 plates at 48 hours. Each
809 datapoint in the graph is the CFU/ml for each sample expressed relative to the average
810 CFU/ml in *Mtb*-infected WT neutrophil cultures within the same experiment. Each
811 datapoint is from a single well compiled from two independent experiments. Bar graph
812 of data represents mean \pm SEM. ****P < 0.0001 by one-way ANOVA with Tukey's
813 correction. BioRender.com used in schematic.

814 **(B)** Analysis of normalized gene expression data from lungs of C57BL/6J or C3HeB/FeJ
815 mice uninfected or infected with low dose Lineage 4 H37Rv *Mtb* strain or Lineage 2
816 HN878 *Mtb* strain. The expression data was obtained from
817 <https://ogarra.shinyapps.io/tbtranscriptome/>. Bar graph of data represents mean, where
818 ****P < 0.0001 by one-way ANOVA with Tukey's correction.

819 **(C)** Schematic of experimental design for *Mtb* HN878 aerosol infection of C3HeB/FeJ
820 mice followed by intraperitoneal injection with 10 mg/kg of BB-CI-amidine or DMSO
821 vehicle every other day from day 11 post-infection until lungs and spleens were
822 harvested at 21 dpi for analysis. N=9 mice per condition compiled from 2 independent
823 experiments.

824 **(D)** Representative images showing immunofluorescence staining of lung sections from
825 *Mtb*-infected C3HeB/FeJ mice that were probed with antibodies to detect citrullinated
826 histone H3 (H3Cit; red), myeloperoxidase (MPO, green, a marker for neutrophil
827 granules), Ly6G (yellow, a marker for neutrophils) and DNA (Hoechst, blue). The entire
828 lung section is shown along with a 60x zoomed in region denoted by the white box. The
829 white arrows point to colocalization of H3Cit, DAPI, and Ly6G staining, indicating the
830 presence of NETing neutrophils.

831 **(E)** Bacterial burdens in the lungs (left) and spleen (right) at 21 dpi were determined by
832 plating dilutions of the organ homogenate onto 7H11 agar plates to numerate CFUs.
833 Each datapoint is the CFU/ml for a single mouse relative to the average CFU/ml in
834 DMSO vehicle treated mice within the same experiment. Data are log₁₀ transformed and
835 the error bars represent the mean \pm SEM. **P < 0.01 determined by unpaired t test.

836

837 **Figure 6. NETosis occurs in necrotic granulomas from *Mtb*-infected cynomolgus**
838 **macaques.**

839 **(A)** Lung tissue from a cynomolgus macaque containing two necrotic granulomas (blue
840 and pink arrowheads) and a non-necrotic granuloma (yellow arrowhead) was stained to
841 visualize neutrophils (S100A9; red), H3Cit (green), and nuclei (DAPI, grey). Few H3Cit⁺
842 cells and neutrophils are present in the non-necrotic granuloma, whereas the necrotic
843 granulomas are characterized by their robust populations of H3Cit⁺ neutrophils. 20x
844 magnification; scale bar represents 500 μ m.

845 **(B)** A necrotic granuloma (larger lesion, center) with a small necrotizing lesion (upper
846 left) that is disseminated from the larger lesion where each granuloma contains

847 numerous H3Cit⁺ and H3Cit⁻ neutrophils in regions adjacent to caseum. 20x
848 magnification, scale bar represents 500 μ m.

849 **(C)** H3Cit⁺ neutrophils are largely absent from a non-necrotic granuloma. 20X
850 magnification; scale bar represents 250 μ m.

851 **(D)** Adjacent foci in a neutrophilic granuloma stained for nuclei (DAPI, grey), S100A9
852 (red), and H3Cit (green) (left panel) suggest that neutrophil recruitment and NETosis
853 are dynamic processes. Region 1 (top panels, right) indicates a neutrophilic region with
854 intact-appearing nuclei, strong S100A9 staining, and sparse H3Cit staining that
855 contrasts with Region 2 (middle panels, right), a necrotic region with diffusely stained
856 DNA suggestive of nuclear breakdown, dim S100A9 staining, and strong H3Cit
857 expression. Scale bar represents 100 μ m or 40 μ m for the left and right panels,
858 respectively. Region 3 highlights a S100A9⁺ neutrophil that is releasing web-like H3Cit⁺
859 DNA. Region 3 scale bar represents 10 μ m.

860

861 **Figure 7. NETosis occurs in proximity to caseum and IFN α 2-expressing**
862 **epithelioid macrophages.**

863 **(A,B)** Cynomolgus macaque granulomas were stained for (A) IFN α 2 (red), H3Cit
864 (green), CD11c (blue, a marker for macrophages and dendritic cells), and nuclei (DAPI,
865 gray) or (B) pIRF3 (red), S100A9 (green, neutrophil marker), CD11c (blue), and nuclei
866 (DAPI, gray). Cells in the imaged sections (left) were segmented into subsets and
867 plotted against the position of all the cells in the granuloma (grey) to highlight the spatial
868 position of macrophages that may be expressing IFN α 2 (red) in context with CD11c⁺

869 macrophages, H3Cit⁺ cells, and neutrophils (right panels). 20x magnification; scale bars
870 represent 100 μ m.

871 **(C)** H3Cit⁺ neutrophils (green) accumulate at the caseum-epithelioid macrophage
872 interface in severely inflamed tissues (region 1) but are also present in small focal
873 regions that may represent early sites of caseation (region 2). Dotted lines represent the
874 border of regions containing cells with intact nuclei and degraded DNA that is indicative
875 of caseation. 20x magnification; scale bar represents 500 μ m in the whole tissue image
876 (left) and 100 μ m in the zoomed in regions (middle and right).

877

878 REFERENCES

879

- 880 1. World Health Organization (2021). Global tuberculosis report 2021.
881 <https://www.who.int/publications/i/item/9789240037021>
- 882 2. Eum, S.-Y., Kong, J.-H., Hong, M.-S., Lee, Y.-J., Kim, J.-H., Hwang, S.-H., Cho, S.-N.,
883 Via, L.E., and Barry, C.E. (2010). Neutrophils Are the Predominant Infected Phagocytic
884 Cells in the Airways of Patients With Active Pulmonary TB. *Chest* *137*, 122–128.
885 [10.1378/chest.09-0903](https://doi.org/10.1378/chest.09-0903).
- 886 3. Condos, R., Rom, W.N., Liu, Y.M., and Schluger, N.W. (1998). Local immune responses
887 correlate with presentation and outcome in tuberculosis. *Am. J. Respir. Crit. Care Med.*
888 *157*, 729–735. [10.1164/ajrccm.157.3.9705044](https://doi.org/10.1164/ajrccm.157.3.9705044).
- 889 4. Eruslanov, E.B., Lyadova, I.V., Kondratieva, T.K., Majorov, K.B., Scheglov, I.V., Orlova,
890 M.O., and Apt, A.S. (2005). Neutrophil responses to *Mycobacterium tuberculosis* infection

- 891 in genetically susceptible and resistant mice. *Infect. Immun.* 73, 1744–1753.
892 10.1128/IAI.73.3.1744-1753.2005.
- 893 5. Lázár-Molnár, E., Chen, B., Sweeney, K.A., Wang, E.J., Liu, W., Lin, J., Porcelli, S.A.,
894 Almo, S.C., Nathenson, S.G., and Jacobs, W.R. (2010). Programmed death-1 (PD-1)–
895 deficient mice are extraordinarily sensitive to tuberculosis. *Proc. Natl. Acad. Sci.* 107,
896 13402–13407. 10.1073/pnas.1007394107.
- 897 6. Nandi, B., and Behar, S.M. (2011). Regulation of neutrophils by interferon- γ limits lung
898 inflammation during tuberculosis infection. *J. Exp. Med.* 208, 2251–2262.
899 10.1084/jem.20110919.
- 900 7. Yeremeev, V., Linge, I., Kondratieva, T., and Apt, A. (2015). Neutrophils exacerbate
901 tuberculosis infection in genetically susceptible mice. *Tuberc. Edinb. Scotl.* 95, 447–451.
902 10.1016/j.tube.2015.03.007.
- 903 8. Mishra, B.B., Lovewell, R.R., Olive, A.J., Zhang, G., Wang, W., Eugenin, E., Smith, C.M.,
904 Phuah, J.Y., Long, J.E., Dubuke, M.L., et al. (2017). Nitric oxide prevents a pathogen-
905 permissive granulocytic inflammation during tuberculosis. *Nat. Microbiol.* 2, 17072.
906 10.1038/nmicrobiol.2017.72.
- 907 9. Moreira-Teixeira, L., Stimpson, P.J., Stavropoulos, E., Hadebe, S., Chakravarty, P.,
908 Ioannou, M., Aramburu, I.V., Herbert, E., Priestnall, S.L., Suarez-Bonnet, A., et al. (2020).
909 Type I IFN exacerbates disease in tuberculosis-susceptible mice by inducing neutrophil-
910 mediated lung inflammation and NETosis. *Nat. Commun.* 11, 5566. 10.1038/s41467-020-
911 19412-6.

- 912 10. Smith, C.M., Baker, R.E., Proulx, M.K., Mishra, B.B., Long, J.E., Park, S.W., Lee, H.-N.,
913 Kiritsy, M.C., Bellerose, M.M., Olive, A.J., et al. (2022). Host-pathogen genetic
914 interactions underlie tuberculosis susceptibility in genetically diverse mice. *eLife* *11*,
915 e74419. [10.7554/eLife.74419](https://doi.org/10.7554/eLife.74419).
- 916 11. Kimmey, J.M., Huynh, J.P., Weiss, L.A., Park, S., Kambal, A., Debnath, J., Virgin, H.W.,
917 and Stallings, C.L. (2015). Unique role for ATG5 in neutrophil-mediated immunopathology
918 during *M. tuberculosis* infection. *Nature* *528*, 565–569. [10.1038/nature16451](https://doi.org/10.1038/nature16451).
- 919 12. Nair, S., Huynh, J.P., Lampropoulou, V., Loginicheva, E., Esaulova, E., Gounder, A.P.,
920 Boon, A.C.M., Schwarzkopf, E.A., Bradstreet, T.R., Edelson, B.T., et al. (2018). *Irg1*
921 expression in myeloid cells prevents immunopathology during *M. tuberculosis* infection. *J.*
922 *Exp. Med.* *215*, 1035–1045. [10.1084/jem.20180118](https://doi.org/10.1084/jem.20180118).
- 923 13. Huynh, J.P., Lin, C.-C., Kimmey, J.M., Jarjour, N.N., Schwarzkopf, E.A., Bradstreet, T.R.,
924 Shchukina, I., Shpynov, O., Weaver, C.T., Taneja, R., et al. (2018). *Bhlhe40* is an essential
925 repressor of IL-10 during *Mycobacterium tuberculosis* infection. *J. Exp. Med.* *215*, 1823–
926 1838. [10.1084/jem.20171704](https://doi.org/10.1084/jem.20171704).
- 927 14. Dorhoi, A., Yermeev, V., Nouailles, G., Weiner, J., Jörg, S., Heinemann, E., Oberbeck-
928 Müller, D., Knaul, J.K., Vogelzang, A., Reece, S.T., et al. (2014). Type I IFN signaling
929 triggers immunopathology in tuberculosis-susceptible mice by modulating lung phagocyte
930 dynamics. *Eur. J. Immunol.* *44*, 2380–2393. [10.1002/eji.201344219](https://doi.org/10.1002/eji.201344219).

- 931 15. Dorhoi, A., Desel, C., Yermeev, V., Pradl, L., Brinkmann, V., Mollenkopf, H.-J., Hanke,
932 K., Gross, O., Ruland, J., and Kaufmann, S.H.E. (2010). The adaptor molecule CARD9 is
933 essential for tuberculosis control. *J. Exp. Med.* *207*, 777–792. [10.1084/jem.20090067](https://doi.org/10.1084/jem.20090067).
- 934 16. Niazi, M.K.K., Dhulekar, N., Schmidt, D., Major, S., Cooper, R., Abeijon, C., Gatti, D.M.,
935 Kramnik, I., Yener, B., Gurcan, M., et al. (2015). Lung necrosis and neutrophils reflect
936 common pathways of susceptibility to *Mycobacterium tuberculosis* in genetically diverse,
937 immune-competent mice. *Dis. Model. Mech.* *8*, 1141–1153. [10.1242/dmm.020867](https://doi.org/10.1242/dmm.020867).
- 938 17. Keller, C., Hoffmann, R., Lang, R., Brandau, S., Hermann, C., and Ehlers, S. (2006).
939 Genetically determined susceptibility to tuberculosis in mice causally involves accelerated
940 and enhanced recruitment of granulocytes. *Infect. Immun.* *74*, 4295–4309.
941 [10.1128/IAI.00057-06](https://doi.org/10.1128/IAI.00057-06).
- 942 18. Gopal, R., Monin, L., Torres, D., Slight, S., Mehra, S., McKenna, K.C., Fallert Junecko,
943 B.A., Reinhart, T.A., Kolls, J., Báez-Saldaña, R., et al. (2013). S100A8/A9 Proteins
944 Mediate Neutrophilic Inflammation and Lung Pathology during Tuberculosis. *Am. J.*
945 *Respir. Crit. Care Med.* *188*, 1137–1146. [10.1164/rccm.201304-0803OC](https://doi.org/10.1164/rccm.201304-0803OC).
- 946 19. Mattila, J.T., Maiello, P., Sun, T., Via, L.E., and Flynn, J.L. (2015). Granzyme B-
947 expressing neutrophils correlate with bacterial load in granulomas from *Mycobacterium*
948 tuberculosis-infected cynomolgus macaques. *Cell. Microbiol.* *17*, 1085–1097.
949 [10.1111/cmi.12428](https://doi.org/10.1111/cmi.12428).

- 950 20. Hult, C., Mattila, J.T., Gideon, H.P., Linderman, J.J., and Kirschner, D.E. (2021).
951 Neutrophil Dynamics Affect Mycobacterium tuberculosis Granuloma Outcomes and
952 Dissemination. *Front. Immunol.* *12*, 712457. [10.3389/fimmu.2021.712457](https://doi.org/10.3389/fimmu.2021.712457).
- 953 21. Gideon, H.P., Phuah, J., Junecko, B.A., and Mattila, J.T. (2019). Neutrophils express pro-
954 and anti-inflammatory cytokines in granulomas from Mycobacterium tuberculosis-infected
955 cynomolgus macaques. *Mucosal Immunol.* *12*, 1370–1381. [10.1038/s41385-019-0195-8](https://doi.org/10.1038/s41385-019-0195-8).
- 956 22. Ozaki, T., Nakahira, S., Tani, K., Ogushi, F., Yasuoka, S., and Ogura, T. (1992).
957 Differential cell analysis in bronchoalveolar lavage fluid from pulmonary lesions of patients
958 with tuberculosis. *Chest* *102*, 54–59. [10.1378/chest.102.1.54](https://doi.org/10.1378/chest.102.1.54).
- 959 23. Brahmhatt, S., Black, G.F., Carroll, N.M., Beyers, N., Salker, F., Kidd, M., Lukey, P.T.,
960 Duncan, K., van Helden, P., and Walzl, G. (2006). Immune markers measured before
961 treatment predict outcome of intensive phase tuberculosis therapy. *Clin. Exp. Immunol.*
962 *146*, 243–252. [10.1111/j.1365-2249.2006.03211.x](https://doi.org/10.1111/j.1365-2249.2006.03211.x).
- 963 24. Berry, M.P.R., Graham, C.M., McNab, F.W., Xu, Z., Bloch, S.A.A., Oni, T., Wilkinson,
964 K.A., Banchereau, R., Skinner, J., Wilkinson, R.J., et al. (2010). An Interferon-Inducible
965 Neutrophil-Driven Blood Transcriptional Signature in Human Tuberculosis. *Nature* *466*,
966 973–977. [10.1038/nature09247](https://doi.org/10.1038/nature09247).
- 967 25. Lowe, D.M., Bandara, A.K., Packe, G.E., Barker, R.D., Wilkinson, R.J., Griffiths, C.J., and
968 Martineau, A.R. (2013). Neutrophilia independently predicts death in tuberculosis. *Eur.*
969 *Respir. J.* *42*, 1752–1757. [10.1183/09031936.00140913](https://doi.org/10.1183/09031936.00140913).

- 970 26. Ashitani, J., Mukae, H., Hiratsuka, T., Nakazato, M., Kumamoto, K., and Matsukura, S.
971 (2002). Elevated Levels of α -Defensins in Plasma and BAL Fluid of Patients With Active
972 Pulmonary Tuberculosis. *Chest* *121*, 519–526. [10.1378/chest.121.2.519](https://doi.org/10.1378/chest.121.2.519).
- 973 27. Jones, T.P.W., Dabbaj, S., Mandal, I., Cleverley, J., Cash, C., Lipman, M.C.I., and Lowe,
974 D.M. (2021). The Blood Neutrophil Count After 1 Month of Treatment Predicts the
975 Radiologic Severity of Lung Disease at Treatment End. *Chest* *160*, 2030–2041.
976 [10.1016/j.chest.2021.07.041](https://doi.org/10.1016/j.chest.2021.07.041).
- 977 28. Scott, N.R., Swanson, R.V., Al-Hammadi, N., Domingo-Gonzalez, R., Rangel-Moreno, J.,
978 Kriel, B.A., Bucsan, A.N., Das, S., Ahmed, M., Mehra, S., et al. (2020). S100A8/A9
979 regulates CD11b expression and neutrophil recruitment during chronic tuberculosis. *J. Clin.*
980 *Invest.* *130*, 3098–3112. [10.1172/JCI130546](https://doi.org/10.1172/JCI130546).
- 981 29. Teng, T.-S., Ji, A.-L., Ji, X.-Y., and Li, Y.-Z. (2017). Neutrophils and Immunity: From
982 Bactericidal Action to Being Conquered. *J. Immunol. Res.* *2017*, 9671604.
983 [10.1155/2017/9671604](https://doi.org/10.1155/2017/9671604).
- 984 30. Denis, M. (1991). Human neutrophils, activated with cytokines or not, do not kill virulent
985 *Mycobacterium tuberculosis*. *J. Infect. Dis.* *163*, 919–920. [10.1093/infdis/163.4.919](https://doi.org/10.1093/infdis/163.4.919).
- 986 31. Corleis, B., Korbel, D., Wilson, R., Bylund, J., Chee, R., and Schaible, U.E. (2012). Escape
987 of *Mycobacterium tuberculosis* from oxidative killing by neutrophils. *Cell. Microbiol.* *14*,
988 1109–1121. [10.1111/j.1462-5822.2012.01783.x](https://doi.org/10.1111/j.1462-5822.2012.01783.x).
- 989 32. Dallenga, T., Repnik, U., Corleis, B., Eich, J., Reimer, R., Griffiths, G.W., and Schaible,
990 U.E. (2017). *M. tuberculosis*-Induced Necrosis of Infected Neutrophils Promotes Bacterial

- 991 Growth Following Phagocytosis by Macrophages. *Cell Host Microbe* 22, 519-530.e3.
992 10.1016/j.chom.2017.09.003.
- 993 33. Martineau, A.R., Newton, S.M., Wilkinson, K.A., Kampmann, B., Hall, B.M., Nawroly, N.,
994 Packe, G.E., Davidson, R.N., Griffiths, C.J., and Wilkinson, R.J. (2007). Neutrophil-
995 mediated innate immune resistance to mycobacteria. *J. Clin. Invest.* 117, 1988–1994.
996 10.1172/JCI31097.
- 997 34. Lowe, D.M., Demaret, J., Bangani, N., Nakiwala, J.K., Goliath, R., Wilkinson, K.A.,
998 Wilkinson, R.J., and Martineau, A.R. (2018). Differential Effect of Viable Versus Necrotic
999 Neutrophils on *Mycobacterium tuberculosis* Growth and Cytokine Induction in Whole
1000 Blood. *Front. Immunol.* 9, 903. 10.3389/fimmu.2018.00903.
- 1001 35. Brown, A.E., Holzer, T.J., and Andersen, B.R. (1987). Capacity of human neutrophils to
1002 kill *Mycobacterium tuberculosis*. *J. Infect. Dis.* 156, 985–989. 10.1093/infdis/156.6.985.
- 1003 36. Kisich, K.O., Higgins, M., Diamond, G., and Heifets, L. (2002). Tumor necrosis factor
1004 alpha stimulates killing of *Mycobacterium tuberculosis* by human neutrophils. *Infect.*
1005 *Immun.* 70, 4591–4599. 10.1128/IAI.70.8.4591-4599.2002.
- 1006 37. Ramos-Kichik, V., Mondragón-Flores, R., Mondragón-Castelán, M., Gonzalez-Pozos, S.,
1007 Muñoz-Hernandez, S., Rojas-Espinosa, O., Chacón-Salinas, R., Estrada-Parra, S., and
1008 Estrada-García, I. (2009). Neutrophil extracellular traps are induced by *Mycobacterium*
1009 *tuberculosis*. *Tuberculosis* 89, 29–37. 10.1016/j.tube.2008.09.009.
- 1010 38. Filio-Rodríguez, G., Estrada-García, I., Arce-Paredes, P., Moreno-Altamirano, M.M., Islas-
1011 Trujillo, S., Ponce-Regalado, M.D., and Rojas-Espinosa, O. (2017). In vivo induction of

- 1012 neutrophil extracellular traps by *Mycobacterium tuberculosis* in a guinea pig model. *Innate*
1013 *Immun.* *23*, 625–637. [10.1177/1753425917732406](https://doi.org/10.1177/1753425917732406).
- 1014 39. Braian, C., Hoge, V., and Stendahl, O. (2013). *Mycobacterium tuberculosis*- induced
1015 neutrophil extracellular traps activate human macrophages. *J. Innate Immun.* *5*, 591–602.
1016 [10.1159/000348676](https://doi.org/10.1159/000348676).
- 1017 40. Chinta, K.C., Rahman, M.A., Saini, V., Glasgow, J.N., Reddy, V.P., Lever, J.M.,
1018 Nhamoyebonde, S., Leslie, A., Wells, R.M., Traylor, A., et al. (2019). Microanatomic
1019 Distribution of Myeloid Heme Oxygenase-1 Protects against Free Radical-Mediated
1020 Immunopathology in Human Tuberculosis. *Cell Rep.* *28*, 3286.
1021 [10.1016/j.celrep.2019.08.081](https://doi.org/10.1016/j.celrep.2019.08.081).
- 1022 41. van der Meer, A.J., Zeerleder, S., Blok, D.C., Kager, L.M., Lede, I.O., Rahman, W., Afroz,
1023 R., Ghose, A., Visser, C.E., Zahed, A.S.M., et al. (2017). Neutrophil extracellular traps in
1024 patients with pulmonary tuberculosis. *Respir. Res.* *18*, 181. [10.1186/s12931-017-0663-1](https://doi.org/10.1186/s12931-017-0663-1).
- 1025 42. Schechter, M.C., Buac, K., Adekambi, T., Cagle, S., Celli, J., Ray, S.M., Mehta, C.C.,
1026 Rada, B., and Rengarajan, J. (2017). Neutrophil extracellular trap (NET) levels in human
1027 plasma are associated with active TB. *PloS One* *12*, e0182587.
1028 [10.1371/journal.pone.0182587](https://doi.org/10.1371/journal.pone.0182587).
- 1029 43. Arita, K., Hashimoto, H., Shimizu, T., Nakashima, K., Yamada, M., and Sato, M. (2004).
1030 Structural basis for Ca(2+)-induced activation of human PAD4. *Nat. Struct. Mol. Biol.* *11*,
1031 777–783. [10.1038/nsmb799](https://doi.org/10.1038/nsmb799).

- 1032 44. Sur Chowdhury, C., Giaglis, S., Walker, U.A., Buser, A., Hahn, S., and Hasler, P. (2014).
1033 Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: analysis of
1034 underlying signal transduction pathways and potential diagnostic utility. *Arthritis Res.*
1035 *Ther.* 16, R122. 10.1186/ar4579.
- 1036 45. Leshner, M., Wang, S., Lewis, C., Zheng, H., Chen, X.A., Santy, L., and Wang, Y. (2012).
1037 PAD4 mediated histone hypercitrullination induces heterochromatin decondensation and
1038 chromatin unfolding to form neutrophil extracellular trap-like structures. *Front. Immunol.* 3,
1039 307. 10.3389/fimmu.2012.00307.
- 1040 46. Brinkmann, V., Reichard, U., Goosmann, C., Fauler, B., Uhlemann, Y., Weiss, D.S.,
1041 Weinrauch, Y., and Zychlinsky, A. (2004). Neutrophil extracellular traps kill bacteria.
1042 *Science* 303, 1532–1535. 10.1126/science.1092385.
- 1043 47. Fuchs, T.A., Abed, U., Goosmann, C., Hurwitz, R., Schulze, I., Wahn, V., Weinrauch, Y.,
1044 Brinkmann, V., and Zychlinsky, A. (2007). Novel cell death program leads to neutrophil
1045 extracellular traps. *J. Cell Biol.* 176, 231–241. 10.1083/jcb.200606027.
- 1046 48. Riyapa, D., Buddhisa, S., Korbsrisate, S., Cuccui, J., Wren, B.W., Stevens, M.P., Ato, M.,
1047 and Lertmemongkolchai, G. (2012). Neutrophil extracellular traps exhibit antibacterial
1048 activity against *Burkholderia pseudomallei* and are influenced by bacterial and host factors.
1049 *Infect. Immun.* 80, 3921–3929. 10.1128/IAI.00806-12.
- 1050 49. Steger, C. (1998). An unbiased detector of curvilinear structures. *IEEE Trans. Pattern Anal.*
1051 *Mach. Intell.* 20, 113–125. 10.1109/34.659930.

- 1052 50. Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T.,
1053 Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012). Fiji: an open-source
1054 platform for biological-image analysis. *Nat. Methods* 9, 676–682. 10.1038/nmeth.2019.
- 1055 51. Keshari, R.S., Verma, A., Barthwal, M.K., and Dikshit, M. (2013). Reactive oxygen
1056 species-induced activation of ERK and p38 MAPK mediates PMA-induced NETs release
1057 from human neutrophils. *J. Cell. Biochem.* 114, 532–540. 10.1002/jcb.24391.
- 1058 52. Neeli, I., Khan, S.N., and Radic, M. (2008). Histone deimination as a response to
1059 inflammatory stimuli in neutrophils. *J. Immunol. Baltim. Md 1950* 180, 1895–1902.
1060 10.4049/jimmunol.180.3.1895.
- 1061 53. Parker, H., Dragunow, M., Hampton, M.B., Kettle, A.J., and Winterbourn, C.C. (2012).
1062 Requirements for NADPH oxidase and myeloperoxidase in neutrophil extracellular trap
1063 formation differ depending on the stimulus. *J. Leukoc. Biol.* 92, 841–849.
1064 10.1189/jlb.1211601.
- 1065 54. Pilszczek, F.H., Salina, D., Poon, K.K.H., Fahey, C., Yipp, B.G., Sibley, C.D., Robbins,
1066 S.M., Green, F.H.Y., Surette, M.G., Sugai, M., et al. (2010). A novel mechanism of rapid
1067 nuclear neutrophil extracellular trap formation in response to *Staphylococcus aureus*. *J.*
1068 *Immunol. Baltim. Md 1950* 185, 7413–7425. 10.4049/jimmunol.1000675.
- 1069 55. Clark, S.R., Ma, A.C., Tavener, S.A., McDonald, B., Goodarzi, Z., Kelly, M.M., Patel,
1070 K.D., Chakrabarti, S., McAvoy, E., Sinclair, G.D., et al. (2007). Platelet TLR4 activates
1071 neutrophil extracellular traps to ensnare bacteria in septic blood. *Nat. Med.* 13, 463–469.
1072 10.1038/nm1565.

- 1073 56. Yipp, B.G., Petri, B., Salina, D., Jenne, C.N., Scott, B.N.V., Zbytnuik, L.D., Pittman, K.,
1074 Asaduzzaman, M., Wu, K., Meijndert, H.C., et al. (2012). Dynamic NETosis is Carried Out
1075 by Live Neutrophils in Human and Mouse Bacterial Abscesses and During Severe Gram-
1076 Positive Infection. *Nat. Med.* *18*, 1386–1393. [10.1038/nm.2847](https://doi.org/10.1038/nm.2847).
- 1077 57. Byrd, A.S., O’Brien, X.M., Johnson, C.M., Lavigne, L.M., and Reichner, J.S. (2013). An
1078 extracellular matrix-based mechanism of rapid neutrophil extracellular trap formation in
1079 response to *Candida albicans*. *J. Immunol. Baltim. Md 1950* *190*, 4136–4148.
1080 [10.4049/jimmunol.1202671](https://doi.org/10.4049/jimmunol.1202671).
- 1081 58. Thiam, H.R., Wong, S.L., Qiu, R., Kittisopikul, M., Vahabikashi, A., Goldman, A.E.,
1082 Goldman, R.D., Wagner, D.D., and Waterman, C.M. (2020). NETosis proceeds by
1083 cytoskeleton and endomembrane disassembly and PAD4-mediated chromatin
1084 decondensation and nuclear envelope rupture. *Proc. Natl. Acad. Sci. U. S. A.* *117*, 7326–
1085 7337. [10.1073/pnas.1909546117](https://doi.org/10.1073/pnas.1909546117).
- 1086 59. Wang, Y., Li, M., Stadler, S., Correll, S., Li, P., Wang, D., Hayama, R., Leonelli, L., Han,
1087 H., Grigoryev, S.A., et al. (2009). Histone hypercitullination mediates chromatin
1088 decondensation and neutrophil extracellular trap formation. *J. Cell Biol.* *184*, 205–213.
1089 [10.1083/jcb.200806072](https://doi.org/10.1083/jcb.200806072).
- 1090 60. Li, P., Li, M., Lindberg, M.R., Kennett, M.J., Xiong, N., and Wang, Y. (2010). PAD4 is
1091 essential for antibacterial innate immunity mediated by neutrophil extracellular traps. *J.*
1092 *Exp. Med.* *207*, 1853–1862. [10.1084/jem.20100239](https://doi.org/10.1084/jem.20100239).

- 1093 61. Su, R., Peng, Y., Deng, Z., Deng, Y., Ye, J., Guo, Y., Huang, Z., Luo, Q., Jiang, H., and Li,
1094 J. (2019). Mycobacterium tuberculosis Infection Induces Low-Density Granulocyte
1095 Generation by Promoting Neutrophil Extracellular Trap Formation via ROS Pathway.
1096 *Front. Microbiol.* *10*, 1468. [10.3389/fmicb.2019.01468](https://doi.org/10.3389/fmicb.2019.01468).
- 1097 62. Tatsiy, O., and McDonald, P.P. (2018). Physiological Stimuli Induce PAD4-Dependent,
1098 ROS-Independent NETosis, With Early and Late Events Controlled by Discrete Signaling
1099 Pathways. *Front. Immunol.* *9*, 2036. [10.3389/fimmu.2018.02036](https://doi.org/10.3389/fimmu.2018.02036).
- 1100 63. Holmes, C.L., Shim, D., Kernien, J., Johnson, C.J., Nett, J.E., and Shelef, M.A. (2019).
1101 Insight into Neutrophil Extracellular Traps through Systematic Evaluation of Citrullination
1102 and Peptidylarginine Deiminases. *J. Immunol. Res.* *2019*, 2160192. [10.1155/2019/2160192](https://doi.org/10.1155/2019/2160192).
- 1103 64. Papayannopoulos, V., Metzler, K.D., Hakkim, A., and Zychlinsky, A. (2010). Neutrophil
1104 elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. *J.*
1105 *Cell Biol.* *191*, 677–691. [10.1083/jcb.201006052](https://doi.org/10.1083/jcb.201006052).
- 1106 65. Metzler, K.D., Goosmann, C., Lubojemska, A., Zychlinsky, A., and Papayannopoulos, V.
1107 (2014). A myeloperoxidase-containing complex regulates neutrophil elastase release and
1108 actin dynamics during NETosis. *Cell Rep.* *8*, 883–896. [10.1016/j.celrep.2014.06.044](https://doi.org/10.1016/j.celrep.2014.06.044).
- 1109 66. Claushuis, T.A.M., van der Donk, L.E.H., Luitse, A.L., van Veen, H.A., van der Wel, N.N.,
1110 van Vught, L.A., Roelofs, J.J.T.H., de Boer, O.J., Lankelma, J.M., Boon, L., et al. (2018).
1111 Role of Peptidylarginine Deiminase 4 in Neutrophil Extracellular Trap Formation and Host
1112 Defense during *Klebsiella pneumoniae*-Induced Pneumonia-Derived Sepsis. *J. Immunol.*
1113 *Baltim. Md* *1950* *201*, 1241–1252. [10.4049/jimmunol.1800314](https://doi.org/10.4049/jimmunol.1800314).

- 1114 67. Silva, J.C., Rodrigues, N.C., Thompson-Souza, G.A., Muniz, V. de S., Neves, J.S., and
1115 Figueiredo, R.T. (2020). Mac-1 triggers neutrophil DNA extracellular trap formation to
1116 *Aspergillus fumigatus* independently of PAD4 histone citrullination. *J. Leukoc. Biol.* *107*,
1117 69–83. [10.1002/JLB.4A0119-009RR](https://doi.org/10.1002/JLB.4A0119-009RR).
- 1118 68. Sebina, I., Rashid, R.B., Sikder, M.A.A., Rahman, M.M., Ahmed, T., Radford-Smith, D.E.,
1119 Kotenko, S.V., Hill, G.R., Bald, T., and Phipps, S. (2022). IFN- λ Diminishes the Severity
1120 of Viral Bronchiolitis in Neonatal Mice by Limiting NADPH Oxidase-Induced PAD4-
1121 Independent NETosis. *J. Immunol. Baltim. Md 1950*, *ji2100876*.
1122 [10.4049/jimmunol.2100876](https://doi.org/10.4049/jimmunol.2100876).
- 1123 69. Grunwell, J.R., Stephenson, S.T., Mohammad, A.F., Jones, K., Mason, C., Opolka, C., and
1124 Fitzpatrick, A.M. (2020). Differential type I interferon response and primary airway
1125 neutrophil extracellular trap release in children with acute respiratory distress syndrome.
1126 *Sci. Rep.* *10*, 19049. [10.1038/s41598-020-76122-1](https://doi.org/10.1038/s41598-020-76122-1).
- 1127 70. Ma, Y., Wang, M., Jia, J., Meng, J., Teng, J., Zhu, D., Shi, H., Sun, Y., Su, Y., Liu, H., et
1128 al. (2022). Enhanced type I interferon signature induces neutrophil extracellular traps
1129 enriched in mitochondrial DNA in adult-onset Still's disease. *J. Autoimmun.* *127*, 102793.
1130 [10.1016/j.jaut.2022.102793](https://doi.org/10.1016/j.jaut.2022.102793).
- 1131 71. Moreira-Teixeira, L., Tabone, O., Graham, C.M., Singhanian, A., Stavropoulos, E., Redford,
1132 P.S., Chakravarty, P., Priestnall, S.L., Suarez-Bonnet, A., Herbert, E., et al. (2020). Mouse
1133 transcriptome reveals potential signatures of protection and pathogenesis in human
1134 tuberculosis. *Nat. Immunol.* *21*, 464–476. [10.1038/s41590-020-0610-z](https://doi.org/10.1038/s41590-020-0610-z).

- 1135 72. Mattila, J.T., Ojo, O.O., Kepka-Lenhart, D., Marino, S., Kim, J.H., Eum, S.Y., Via, L.E.,
1136 Barry, C.E., Klein, E., Kirschner, D.E., et al. (2013). Microenvironments in tuberculous
1137 granulomas are delineated by distinct populations of macrophage subsets and expression of
1138 nitric oxide synthase and arginase isoforms. *J. Immunol. Baltim. Md 1950* *191*, 773–784.
1139 10.4049/jimmunol.1300113.
- 1140 73. Mattila, J.T., Ojo, O.O., Kepka-Lenhart, D., Marino, S., Kim, J.H., Eum, S.Y., Via, L.E.,
1141 Barry, C.E., Klein, E., Kirschner, D.E., et al. (2013). Microenvironments in tuberculous
1142 granulomas are delineated by distinct populations of macrophage subsets and expression of
1143 nitric oxide synthase and arginase isoforms. *J. Immunol. Baltim. Md 1950* *191*, 773–784.
1144 10.4049/jimmunol.1300113.
- 1145 74. Moreira-Teixeira, L., Mayer-Barber, K., Sher, A., and O’Garra, A. (2018). Type I
1146 interferons in tuberculosis: Foe and occasionally friend. *J. Exp. Med.* *215*, 1273–1285.
1147 10.1084/jem.20180325.
- 1148 75. Murata, H., Kinoshita, M., Yasumizu, Y., Motooka, D., Beppu, S., Shiraishi, N., Sugiyama,
1149 Y., Kihara, K., Tada, S., Koda, T., et al. (2022). Cell-Free DNA Derived From Neutrophils
1150 Triggers Type 1 Interferon Signature in Neuromyelitis Optica Spectrum Disorder. *Neurol.*
1151 *Neuroimmunol. Neuroinflammation* *9*, e1149. 10.1212/NXI.0000000000001149.
- 1152 76. Garcia-Romo, G.S., Caielli, S., Vega, B., Connolly, J., Allantaz, F., Xu, Z., Punaro, M.,
1153 Baisch, J., Guiducci, C., Coffman, R.L., et al. (2011). Netting neutrophils are major
1154 inducers of type I IFN production in pediatric systemic lupus erythematosus. *Sci. Transl.*
1155 *Med.* *3*, 73ra20. 10.1126/scitranslmed.3001201.

- 1156 77. Jena, P., Mohanty, S., Mohanty, T., Kallert, S., Morgelin, M., Lindstrøm, T., Borregaard,
1157 N., Stenger, S., Sonawane, A., and Sørensen, O.E. (2012). Azurophil Granule Proteins
1158 Constitute the Major Mycobactericidal Proteins in Human Neutrophils and Enhance the
1159 Killing of Mycobacteria in Macrophages. *PLoS ONE* 7, e50345.
1160 10.1371/journal.pone.0050345.
- 1161 78. Kalita, A., Verma, I., and Khuller, G.K. (2004). Role of human neutrophil peptide-1 as a
1162 possible adjunct to antituberculosis chemotherapy. *J. Infect. Dis.* 190, 1476–1480.
1163 10.1086/424463.
- 1164 79. Martineau, A.R., Newton, S.M., Wilkinson, K.A., Kampmann, B., Hall, B.M., Nawroly, N.,
1165 Packe, G.E., Davidson, R.N., Griffiths, C.J., and Wilkinson, R.J. (2007). Neutrophil-
1166 mediated innate immune resistance to mycobacteria. *J. Clin. Invest.* 117, 1988–1994.
1167 10.1172/JCI31097.
- 1168 80. Steinwede, K., Maus, R., Bohling, J., Voedisch, S., Braun, A., Ochs, M., Schmiedl, A.,
1169 Länger, F., Gauthier, F., Roes, J., et al. (2012). Cathepsin G and neutrophil elastase
1170 contribute to lung-protective immunity against mycobacterial infections in mice. *J.*
1171 *Immunol. Baltim. Md* 1950 188, 4476–4487. 10.4049/jimmunol.1103346.
- 1172 81. Seper, A., Hosseinzadeh, A., Gorkiewicz, G., Lichtenegger, S., Roier, S., Leitner, D.R.,
1173 Röhm, M., Grutsch, A., Reidl, J., Urban, C.F., et al. (2013). *Vibrio cholerae* evades
1174 neutrophil extracellular traps by the activity of two extracellular nucleases. *PLoS Pathog.* 9,
1175 e1003614. 10.1371/journal.ppat.1003614.

- 1176 82. Pinchuk, G.E., Ammons, C., Culley, D.E., Li, S.-M.W., McLean, J.S., Romine, M.F.,
1177 Nealson, K.H., Fredrickson, J.K., and Beliaev, A.S. (2008). Utilization of DNA as a Sole
1178 Source of Phosphorus, Carbon, and Energy by *Shewanella* spp.: Ecological and
1179 Physiological Implications for Dissimilatory Metal Reduction. *Appl. Environ. Microbiol.*
1180 *74*, 1198–1208. [10.1128/AEM.02026-07](https://doi.org/10.1128/AEM.02026-07).
- 1181 83. Dang, G., Cao, J., Cui, Y., Song, N., Chen, L., Pang, H., and Liu, S. (2016).
1182 Characterization of Rv0888, a Novel Extracellular Nuclease from *Mycobacterium*
1183 *tuberculosis*. *Sci. Rep.* *6*, 19033. [10.1038/srep19033](https://doi.org/10.1038/srep19033).
- 1184 84. Muefong, C.N., Owolabi, O., Donkor, S., Charalambous, S., Mendy, J., Sey, I.C.M.,
1185 Bakuli, A., Rachow, A., Geldmacher, C., and Sutherland, J.S. (2021). Major Neutrophil-
1186 Derived Soluble Mediators Associate With Baseline Lung Pathology and Post-Treatment
1187 Recovery in Tuberculosis Patients. *Front. Immunol.* *12*, 740933.
1188 [10.3389/fimmu.2021.740933](https://doi.org/10.3389/fimmu.2021.740933).
- 1189 85. Elkington, P.T.G., and Friedland, J.S. (2006). Matrix metalloproteinases in destructive
1190 pulmonary pathology. *Thorax* *61*, 259–266. [10.1136/thx.2005.051979](https://doi.org/10.1136/thx.2005.051979).
- 1191 86. Ong, C.W.M., Elkington, P.T., Brilha, S., Ugarte-Gil, C., Tome-Esteban, M.T., Tezera,
1192 L.B., Pabisiak, P.J., Moores, R.C., Sathyamoorthy, T., Patel, V., et al. (2015). Neutrophil-
1193 Derived MMP-8 Drives AMPK-Dependent Matrix Destruction in Human Pulmonary
1194 Tuberculosis. *PLoS Pathog.* *11*, e1004917. [10.1371/journal.ppat.1004917](https://doi.org/10.1371/journal.ppat.1004917).
- 1195 87. Orme, I.M. (2014). A new unifying theory of the pathogenesis of tuberculosis. *Tuberc.*
1196 *Edinb. Scotl.* *94*, 8–14. [10.1016/j.tube.2013.07.004](https://doi.org/10.1016/j.tube.2013.07.004).

- 1197 88. Wong, K.-W., and Jacobs, W.R. (2016). Postprimary Tuberculosis and Macrophage
1198 Necrosis: Is There a Big ConNEction? *mBio* 7, e01589-15. [10.1128/mBio.01589-15](https://doi.org/10.1128/mBio.01589-15).
- 1199 89. Hoff, D.R., Ryan, G.J., Driver, E.R., Ssemakulu, C.C., De Groote, M.A., Basaraba, R.J.,
1200 and Lenaerts, A.J. (2011). Location of Intra- and Extracellular *M. tuberculosis* Populations
1201 in Lungs of Mice and Guinea Pigs during Disease Progression and after Drug Treatment.
1202 *PLoS ONE* 6, e17550. [10.1371/journal.pone.0017550](https://doi.org/10.1371/journal.pone.0017550).
- 1203 90. Chen, L., Zhao, Y., Lai, D., Zhang, P., Yang, Y., Li, Y., Fei, K., Jiang, G., and Fan, J.
1204 (2018). Neutrophil extracellular traps promote macrophage pyroptosis in sepsis. *Cell Death*
1205 *Dis.* 9, 597. [10.1038/s41419-018-0538-5](https://doi.org/10.1038/s41419-018-0538-5).
- 1206 91. Esaulova, E., Das, S., Singh, D.K., Choreño-Parra, J.A., Swain, A., Arthur, L., Rangel-
1207 Moreno, J., Ahmed, M., Singh, B., Gupta, A., et al. (2021). The immune landscape in
1208 tuberculosis reveals populations linked to disease and latency. *Cell Host Microbe* 29, 165-
1209 178.e8. [10.1016/j.chom.2020.11.013](https://doi.org/10.1016/j.chom.2020.11.013).
- 1210 92. Divangahi, M., King, I.L., and Pernet, E. (2015). Alveolar macrophages and type I IFN in
1211 airway homeostasis and immunity. *Trends Immunol.* 36, 307–314.
1212 [10.1016/j.it.2015.03.005](https://doi.org/10.1016/j.it.2015.03.005).
- 1213 93. Murata, H., Kinoshita, M., Yasumizu, Y., Motooka, D., Beppu, S., Shiraishi, N., Sugiyama,
1214 Y., Kihara, K., Tada, S., Koda, T., et al. (2022). Cell-Free DNA Derived From Neutrophils
1215 Triggers Type 1 Interferon Signature in Neuromyelitis Optica Spectrum Disorder. *Neurol.*
1216 *Neuroimmunol. Neuroinflammation* 9, e1149. [10.1212/NXI.0000000000001149](https://doi.org/10.1212/NXI.0000000000001149).

- 1217 94. Lood, C., Blanco, L.P., Purmalek, M.M., Carmona-Rivera, C., De Ravin, S.S., Smith, C.K.,
1218 Malech, H.L., Ledbetter, J.A., Elkon, K.B., and Kaplan, M.J. (2016). Neutrophil
1219 extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and
1220 contribute to lupus-like disease. *Nat. Med.* 22, 146–153. 10.1038/nm.4027.
- 1221 95. Caielli, S., Athale, S., Domic, B., Murat, E., Chandra, M., Banchereau, R., Baisch, J.,
1222 Phelps, K., Clayton, S., Gong, M., et al. (2016). Oxidized mitochondrial nucleoids released
1223 by neutrophils drive type I interferon production in human lupus. *J. Exp. Med.* 213, 697–
1224 713. 10.1084/jem.20151876.
- 1225 96. Lande, R., Ganguly, D., Facchinetti, V., Frasca, L., Conrad, C., Gregorio, J., Meller, S.,
1226 Chamilos, G., Sebasigari, R., Ricciari, V., et al. (2011). Neutrophils activate plasmacytoid
1227 dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus.
1228 *Sci. Transl. Med.* 3, 73ra19. 10.1126/scitranslmed.3001180.
- 1229 97. Garcia-Romo, G.S., Caielli, S., Vega, B., Connolly, J., Allantaz, F., Xu, Z., Punaro, M.,
1230 Baisch, J., Guiducci, C., Coffman, R.L., et al. (2011). Netting neutrophils are major
1231 inducers of type I IFN production in pediatric systemic lupus erythematosus. *Sci. Transl.*
1232 *Med.* 3, 73ra20. 10.1126/scitranslmed.3001201.
- 1233 98. Kimmey, J.M., Campbell, J.A., Weiss, L.A., Monte, K.J., Lenschow, D.J., and Stallings,
1234 C.L. (2017). The impact of ISGylation during *Mycobacterium tuberculosis* infection in
1235 mice. *Microbes Infect.* 19, 249–258. 10.1016/j.micinf.2016.12.006.
- 1236 99. Manca, C., Tsenova, L., Freeman, S., Barczak, A.K., Tovey, M., Murray, P.J., Barry, C.,
1237 and Kaplan, G. (2005). Hypervirulent *M. tuberculosis* W/Beijing strains upregulate type I

- 1238 IFNs and increase expression of negative regulators of the Jak-Stat pathway. *J. Interferon*
1239 *Cytokine Res. Off. J. Int. Soc. Interferon Cytokine Res.* 25, 694–701.
1240 10.1089/jir.2005.25.694.
- 1241 100. Braian, C., Hoge, V., and Stendahl, O. (2013). Mycobacterium tuberculosis- induced
1242 neutrophil extracellular traps activate human macrophages. *J. Innate Immun.* 5, 591–602.
1243 10.1159/000348676.
- 1244 101. Monteith, A.J., Miller, J.M., Maxwell, C.N., Chazin, W.J., and Skaar, E.P. (2021).
1245 Neutrophil extracellular traps enhance macrophage killing of bacterial pathogens. *Sci. Adv.*
1246 7, eabj2101. 10.1126/sciadv.abj2101.
- 1247 102. Su, R., Peng, Y., Deng, Z., Deng, Y., Ye, J., Guo, Y., Huang, Z., Luo, Q., Jiang, H., and Li,
1248 J. (2019). Mycobacterium tuberculosis Infection Induces Low-Density Granulocyte
1249 Generation by Promoting Neutrophil Extracellular Trap Formation via ROS Pathway.
1250 *Front. Microbiol.* 10, 1468. 10.3389/fmicb.2019.01468.
- 1251 103. Deng, Y., Ye, J., Luo, Q., Huang, Z., Peng, Y., Xiong, G., Guo, Y., Jiang, H., and Li, J.
1252 (2016). Low-Density Granulocytes Are Elevated in Mycobacterial Infection and Associated
1253 with the Severity of Tuberculosis. *PloS One* 11, e0153567. 10.1371/journal.pone.0153567.
- 1254 104. La Manna, M.P., Orlando, V., Paraboschi, E.M., Tamburini, B., Di Carlo, P., Cascio, A.,
1255 Asselta, R., Dieli, F., and Caccamo, N. (2019). Mycobacterium tuberculosis Drives
1256 Expansion of Low-Density Neutrophils Equipped With Regulatory Activities. *Front.*
1257 *Immunol.* 10, 2761. 10.3389/fimmu.2019.02761.

- 1258 105. Fuchs, T.A., Brill, A., Duerschmied, D., Schatzberg, D., Monestier, M., Myers, D.D.,
1259 Wroblewski, S.K., Wakefield, T.W., Hartwig, J.H., and Wagner, D.D. (2010). Extracellular
1260 DNA traps promote thrombosis. *Proc. Natl. Acad. Sci. U. S. A.* *107*, 15880–15885.
1261 [10.1073/pnas.1005743107](https://doi.org/10.1073/pnas.1005743107).
- 1262 106. Corry, J., Kettenburg, G., Upadhyay, A.A., Wallace, M., Marti, M.M., Wonderlich, E.R.,
1263 Bissel, S.J., Goss, K., Sturgeon, T.J., Watkins, S.C., et al. (2022). Infiltration of
1264 inflammatory macrophages and neutrophils and widespread pyroptosis in lung drive
1265 influenza lethality in nonhuman primates. *PLoS Pathog.* *18*, e1010395.
1266 [10.1371/journal.ppat.1010395](https://doi.org/10.1371/journal.ppat.1010395).
- 1267 107. Narasaraju, T., Yang, E., Samy, R.P., Ng, H.H., Poh, W.P., Liew, A.-A., Phoon, M.C., van
1268 Rooijen, N., and Chow, V.T. (2011). Excessive neutrophils and neutrophil extracellular
1269 traps contribute to acute lung injury of influenza pneumonitis. *Am. J. Pathol.* *179*, 199–210.
1270 [10.1016/j.ajpath.2011.03.013](https://doi.org/10.1016/j.ajpath.2011.03.013).
- 1271 108. Sivanandham, R., Brocca-Cofano, E., Krampe, N., Falwell, E., Venkatraman, S.M.K.,
1272 Ribeiro, R.M., Apetrei, C., and Pandrea, I. (2018). Neutrophil extracellular trap production
1273 contributes to pathogenesis in SIV-infected nonhuman primates. *J. Clin. Invest.* *128*, 5178–
1274 5183. [10.1172/JCI99420](https://doi.org/10.1172/JCI99420).
- 1275 109. Cesta, M.C., Zippoli, M., Marsiglia, C., Gavioli, E.M., Cremonesi, G., Khan, A., Mantelli,
1276 F., Allegretti, M., and Balk, R. Neutrophil activation and neutrophil extracellular traps
1277 (NETs) in COVID-19 ARDS and immunothrombosis. *Eur. J. Immunol.* *n/a*.
1278 [10.1002/eji.202250010](https://doi.org/10.1002/eji.202250010).

- 1279 110. Mócsai, A., Zhang, H., Jakus, Z., Kitaura, J., Kawakami, T., and Lowell, C.A. (2003). G-
1280 protein-coupled receptor signaling in Syk-deficient neutrophils and mast cells. *Blood* *101*,
1281 4155–4163. [10.1182/blood-2002-07-2346](https://doi.org/10.1182/blood-2002-07-2346).
- 1282 111. Lin, P.L., Rodgers, M., Smith, L., Bigbee, M., Myers, A., Bigbee, C., Chiose, I., Capuano,
1283 S.V., Fuhrman, C., Klein, E., et al. (2009). Quantitative comparison of active and latent
1284 tuberculosis in the cynomolgus macaque model. *Infect. Immun.* *77*, 4631–4642.
1285 [10.1128/IAI.00592-09](https://doi.org/10.1128/IAI.00592-09).
- 1286 112. Lin, P.L., Coleman, T., Carney, J.P.J., Lopresti, B.J., Tomko, J., Fillmore, D., Dartois, V.,
1287 Scanga, C., Frye, L.J., Janssen, C., et al. (2013). Radiologic Responses in Cynomolgus
1288 Macaques for Assessing Tuberculosis Chemotherapy Regimens. *Antimicrob. Agents*
1289 *Chemother.* *57*, 4237–4244. [10.1128/AAC.00277-13](https://doi.org/10.1128/AAC.00277-13).
- 1290 113. P, B., Mb, L., Ja, F., Y, D., Dg, M., Pd, D., S, M., Rt, G., Lj, M., Hg, C., et al. (2017).
1291 QuPath: Open source software for digital pathology image analysis. *Sci. Rep.* *7*.
1292 [10.1038/s41598-017-17204-5](https://doi.org/10.1038/s41598-017-17204-5).
- 1293 114. Stoltzfus, C.R., Filipek, J., Gern, B.H., Olin, B.E., Leal, J.M., Wu, Y., Lyons-Cohen, M.R.,
1294 Huang, J.Y., Paz-Stoltzfus, C.L., Plumlee, C.R., et al. (2020). CytoMAP: A Spatial
1295 Analysis Toolbox Reveals Features of Myeloid Cell Organization in Lymphoid Tissues.
1296 *Cell Rep.* *31*, 107523. [10.1016/j.celrep.2020.107523](https://doi.org/10.1016/j.celrep.2020.107523).

1297

1298




1299




1300


1301








1302



1303











bioRxiv preprint doi: <https://doi.org/10.1101/2022.11.28.516376>; this version posted November 28, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

